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Population-based cancer survival is a key measure of the effectiveness of health systems 
in managing cancer. Monitoring survival over time and between countries is also crucial to 
assess inequalities and drive policies for cancer control. 
In this thesis, I use data from the Kuwait Cancer Registry (KCR) to produce a comprehensive 
profile of population-based cancer survival in Kuwait, to enable evaluation of cancer care in 
the country. 
In order to produce robust population-based net survival estimates, it is necessary to have 
the full date of both the cancer diagnosis and the last known vital status for all patients. All 
deaths must be included, irrespective of the cause of death. A new approach to obtain follow-
up data on the vital status of all registered Kuwaiti cancer patients was implemented. This 
enabled the estimation of population-based cancer survival in Kuwait for the first time, using 
robust and unbiased methods that allow comparisons to be made over time and between 
different populations. Further analyses of survival by stage at diagnosis were also 
performed, to provide a deeper understanding of cancer survival in Kuwait. Finally, an 
overall assessment of progress against cancer was performed, using the three main cancer 
control metrics: incidence, survival and mortality. 
The findings demonstrate that survival has improved for many cancers in Kuwait during 
2000-2013. However, further research is required to help dissect the underlying causes of 
the differences in survival between Kuwait and other countries with comparable income and 
health systems. It also highlighted the importance of more complete collection of stage data, 
the necessity of improving early detection, and the need for systematic production and 
assessment of cancer control measures in Kuwait. The findings should assist policymakers 
and practitioners investing in the Kuwaiti healthcare system to achieve optimal outcomes 






This thesis is a research paper style thesis, written in accordance with the London 
School of Hygiene and Tropical Medicine’s guidelines and regulations. It comprises 
two published and two as yet unpublished research papers on population-based 
cancer survival in Kuwait. Although the papers comprise one body of work, they also 
stand alone as independent studies. There are, therefore, several sections where 
definitions and descriptive methodology are repeated. For the two published papers, 
the word-processed versions are included as separate chapters and the publications 
are available in the appendices. Each paper is preceded by a cover letter and a 
preface that includes an introduction and supplementary information. 
The introductory chapter looks at cancer in Kuwait and the importance of the main 
cancer control metrics in informing efforts to control the cancer burden, focusing on 
the importance of population-based cancer survival, followed by the aims and 
objectives. Chapters 2 and 3 include a review of the literature in support of the aim, 
and the description of the main statistical methods used in this thesis. Chapters 4–7 
comprise a series of research papers on cancer survival in Kuwait, starting with the 
method to obtain data on follow-up  for vital status for each patient (chapter 4), the 
estimation of population-based cancer survival in Kuwait (chapter 5), survival by 
stage at diagnosis (chapter 6), and an assessment of overall progress against 
cancer in Kuwait (chapter 7). Chapter 8 presents a discussion of the results of these 
studies, their implications, possible directions for future research, limitations, and an 
overall conclusion. References cited throughout the text, including those in the 
research papers, are listed at the end of the thesis.  
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Figure 1.1 Location of Kuwait 
Chapter 1: Introduction 
___________________________________________________________________________________________________ 
1.1 Kuwait 
Kuwait is an Arab country in Western Asia [Figure 1.1], located at the northern tip of the 
Arabian or Persian Gulf. It covers an area of about 18,000 square kilometres and shares 
borders with Iraq and Saudi Arabia.1 The official language is Arabic, although English is also 
widely spoken.1 Kuwait is a member of the Gulf Cooperation Council (GCC) − along with the 
Kingdom of Bahrain, the Sultanate of Oman, Qatar, the Kingdom of Saudi Arabia and the 
United Arab Emirates − a union of which the members share common objectives, as well as 
political and cultural identities.2 All GCC countries are considered high-income countries.3 
Kuwait enjoys a high economic status, which allows its government to provide citizens with 
many public services and amenities, such as free healthcare, education, retirement income, 























In 2017, the population of Kuwait reached 4,500,476, of which 63% were men and 37% 
women [Figure 1.2]. Kuwaiti nationals represent 30.0% of the total population, with a 1:1 
male to female ratio, while non-Kuwaitis represent 70% of the total population with a 2.3:1 
male to female ratio.5 Non-Kuwaitis are mostly immigrant workers from other Asian and Arab 
countries.6 The age composition of the population pyramid differs markedly between 
Kuwaitis and non-Kuwaitis: for Kuwaitis, the pyramid has a wide base, with proportional 
symmetry between the sexes at each age. This is typical of most Middle Eastern countries 
with low mortality and high fertility rates.7 However, for non-Kuwaitis, the pyramid has a 
narrow base with a wide middle-age group, representing the working age-group; the 
distribution between the sexes in this group is asymmetric. Fertility rates (total births per 
woman) have been decreasing steadily in Kuwait, with rates dropping from 2.9 per 1,000 
women  in 1999 to 2.0 per 1,000 women in 2017.3  In 2015, life expectancy at birth for Kuwaiti 
men and women was 73.2 and 78.0, respectively, while life expectancy for non-Kuwaiti men 
and women was 78.0 and 78.1, respectively (http://csg.lshtm.ac.uk/life-tables/). Life 
expectancy for the total population in Kuwait has also been increasing, reaching 76.8 years 
for men and 79.6 years for women in 2017.1 The population of Kuwait is also projected to 
reach 5 million by 2020, and 7 million in 2030. This population growth is likely to be 



























































1.2 Health care in Kuwait 
Kuwait’s health infrastructure is considered the most modern in the region.4 The majority of 
health services are provided by the public sector, via the Ministry of Health. The Ministry 
provides all citizens with comprehensive primary, secondary and tertiary care, distributed 
via primary health care centres, six general hospitals and many General Practitioner (GP) 
clinics and national specialised hospitals. Citizens also have the option of travelling abroad 
for treatment, when treatment or health services are not available in the hospitals of Kuwait. 
In 2015, health expenditure in Kuwait was 4.0% of the Gross Domestic Product (GDP), 
compared to an average of 4.2% in other GCC countries, 9.8% in the United Kingdom and 
16.8% in the United States.3 In the United Kingdom, almost all the expenditure comes from 
the “public” spend, while in the US it is almost half “public” and half “private”.9 In Kuwait the 
government’s share of the total health expenditure is about 80%, while about 20% comes 
from out-of-pocket payments.10 The Ministry of Health’s budget for 2015-2016 had doubled 
over the previous five years, indicating rapid growth and increasing investment in the 
country’s healthcare infrastructure.10 
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1.3 Cancer in Kuwait 
Non-communicable diseases (NCDs) in Kuwait account for 73% of all deaths. Among the 
NCDs, cancer is the most common cause of death, after cardiovascular diseases [Figure 
1.3]. One of the goals of the 2013 World Cancer Declaration, set by the Union for 
International Cancer Control (UICC), of which the Kuwait Society for Preventing Smoking 
and Cancer is a member, is to achieve worldwide improvement in cancer survival by 2020.11 
In 2013, the Kuwait Cancer Control Centre (KCCC) also established a cancer strategic plan 
for 2013-2018, with one of its goals to ‘measure and improve outcomes’ through ‘measuring 
disease control rates and survival’.12 
 
Figure 1.3 Causes of death in Kuwait, 2014 
 
 




The most common cancers diagnosed during 1998-2012 among Kuwaiti males were 
prostate and colorectal cancer, and leukaemia. The leading cancers among Kuwaiti females 
were breast, thyroid and colorectal cancers [Table 1.1].13 For non-Kuwaitis, the latest report, 
in 2013, indicated that the most commonly diagnosed cancer in men was colorectal, followed 
by prostate cancer and leukaemia, while the leading cancers for non-Kuwaiti women were 
breast followed by thyroid. 
Table 1.1 The most common cancers diagnosed in Kuwait during 1998-2012 
 Kuwaiti Non-Kuwaiti* 
Rank Males Females Males Females 
1 Prostate Breast Colorectal Breast 
2 Colorectal Thyroid Prostate Thyroid 
3 Leukaemia Colorectal Leukaemia Corpus uteri 
            
  *2013 only 
 
1.4 Kuwait Cancer Control Centre 
The Kuwait Cancer Control Centre (KCCC) is the only centre in the country that provides 
the full range of cancer treatment modalities and care. It comprises facilities for specialised 
surgery, radiology and radiotherapy, chemotherapy, bone marrow transplantation, 
laboratory services, paediatric oncology and haematology services, as well as palliative 
care.14 It is the only centre in the country that provides radiotherapy and chemotherapy for 
cancer patients. 
The Kuwait Cancer Registry (KCR), the oldest population-based registry [see Section 1.6] 
in the Gulf region, was established in 1971, with the aim of monitoring cancer incidence in 
Kuwait. In 1982, it was recognised as a separate department in the KCCC.15 The KCR is 
considered to be a comprehensive source of information for all cancer patients diagnosed 
in Kuwait. The KCR registers everyone diagnosed or treated in Kuwait. This includes 
patients diagnosed in the country, patients diagnosed abroad but receiving treatment in the 
KCCC, as well as patients diagnosed in Kuwait but receiving treatment abroad. All hospitals 
in Kuwait are required by law to send copies of the pathology and cytology reports of any 
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malignant neoplasm and specified non-malignant neoplasms, such as those of the brain, to 
the KCR. The registry is a member of the International Association of Cancer Registries 
(IACR) and the Gulf Centre for Cancer Registration (GCCR) and operates according to the 
guidelines of the International Association of Cancer Registries (IACR). 
The KCR maintains a register of all cancer patients, including data on nationality, sex, age, 
year of diagnosis, basis of diagnosis, and on the date of death, which is obtained through 
the Ministry of Health’s Biostatistics Office. The registry is responsible for producing annual 
population-based incidence rates. It also collects information on the death of registered 
patients by manually scanning all the death announcements in Kuwait during a specific 
calendar year; however, it is only able to capture information on deaths due to cancer.  
1.5 Incidence, survival and mortality 
Incidence, survival and mortality are three of the main metrics for monitoring the cancer 
burden. Each measure describes a different aspect of the cancer burden; however, when 
used in isolation, the results can be misleading. A combination of all three measures is 
advised when monitoring the overall progress of cancer control. 
Incidence refers to the number of newly diagnosed cancer patients in a specific population 
or region, over a defined period of time. The incidence rate is usually expressed as the 
number of cancers per 100,000 person-years at risk during a specific time period, typically 
one year. The numerator is the number of patients newly diagnosed with cancer in a specific 
region during a specific time period, and the denominator is the person-years at risk. The 
numerator can be obtained from the cancer registry; the denominator can be approximated 
using the mid-year population of the defined population at risk of the disease, during the 
year of interest. Thus, the incidence rate in a given area or region is given by: 
 
𝑁𝑜. 𝑜𝑓 cancer deaths (𝑖n the relevant year ) 
x 100,000 
𝑁𝑜. 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛𝑠 𝑐𝑜𝑚𝑝𝑟𝑖𝑠𝑖𝑛𝑔  the 𝑚𝑖𝑑-𝑦𝑒𝑎𝑟 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
   
= Mortality 𝑟𝑎𝑡𝑒 𝑝𝑒r 100,000 𝑝𝑒𝑟𝑠𝑜𝑛-𝑦𝑒𝑎𝑟𝑠  
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Cancer mortality refers to the number of deaths that are attributable to cancer in the general 
population during a given period of time, typically a year; and like incidence, it is usually 
expressed as a rate per 100,000 person-years. The numerator, the number of deaths 
attributed to cancer as the underlying cause, is obtained from national statistics agencies, 
and the denominator, the person-years at risk, is again approximated using the mid-year 
population. The mortality rate in a given area or region is given by: 
Population-based cancer survival refers to the cumulative probability for cancer patients in 
a defined region to survive their cancer up to a certain time since diagnosis, after controlling 
for competing risks of death [see Chapter 3 for more detail].  
Incidence is useful in detecting high-risk populations, understanding the aetiology of 
disease, raising awareness, and establishing priorities for primary prevention and planning 
health services. Cancer mortality is useful to set priorities and assess the effects of 
screening programmes, because such programmes are intended to reduce mortality, 
although for some cancers early detection also enables removal of pre-malignant lesions or 
even pre-invasive (in situ) malignant lesions. Population-based cancer survival is considered 
a reliable measure of the effectiveness of the health system in dealing with cancer, either 
curing or prolonging the lives of cancer patients. 
In general, incidence and survival are considered as independent measures. Incidence rates 
for a specific cancer are influenced by events that occur prior to diagnosis, for example, 
changes in exposure to risk factors. Incidence rates can also be influenced by changes in 
the international definitions of malignancy. Survival may be influenced by events that occur 
before and after diagnosis, such as the intensity of diagnostic activity, the thoroughness of 
diagnostic investigation and the availability, accessibility and timeliness of effective 
 
𝑁𝑜. 𝑜𝑓 𝑛𝑒𝑤 𝑐𝑎𝑛𝑐𝑒𝑟s (𝑖n the relevant year) 
x 100,000 
𝑁𝑜. 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛𝑠 𝑐𝑜𝑚𝑝𝑟𝑖𝑠𝑖𝑛𝑔 the 𝑚𝑖𝑑-𝑦𝑒𝑎𝑟 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
   






treatment, as well as post-treatment surveillance and follow-up care. Events after diagnosis 
cannot affect incidence. On the other hand, mortality is influenced by both incidence and 
survival, since a patient’s death due to cancer pre-supposes a diagnosis and a subsequent 
failure to survive the illness.  
Incidence, survival and mortality trends can be combined to provide a more accurate 
representation of the cancer burden, illustrating variations in the impact of cancer between 
population sub-groups and over time. Mortality trends can be misleading when examined in 
isolation, because mortality rates derived from the deaths that occur in a given year depend 
on a combination of previous trends in incidence and survival. Comparisons of mortality 
rates are also based on the assumption that death registration practices are consistent and 
comparable between countries and over time. This assumption is not usually considered 
sound for international studies. Thus, in order to make robust comparisons of the 
effectiveness of the health service over time or between different countries, population-
based survival statistics are more directly interpretable than mortality rates as an indicator 
of outcomes.16 
1.6 Population-based data 
To assess cancer control, population-based cancer data are required. These data can be 
obtained from cancer registries, whose role is to collect, store, analyse and report data 
systematically, for all cancer patients resident in a defined location, such as a country, 
province or state.17-19 
Population-based studies differ in purpose, scope and design from clinical trials; the utility 
and interpretation of the results also differs. In most clinical trials, patients are randomised, 
and the process entails numerous controls and restrictions; such as adhering to a specific 
healthcare plan, excluding less healthy patients with pre-existing medical conditions, and 
possibly certain age groups or ethnicities. This process ensures good internal validity of the 
results, making them less likely to be affected by bias or confounding factors; rendering 
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clinical trials useful in evaluating the efficacy of drugs or other cancer treatment 
interventions. However, while clinical trials inform us about the efficacy of treatments in a 
controlled research setting, they are unable to describe the overall management of cancer 
patients. Typically, less than 10% of adult cancer patients are enrolled in clinical trials, in 
which older patients, and patients with comorbidities or advanced stage are often excluded. 
Trials are also, generally, carried out by doctors and healthcare facilities that are more 
research-oriented. They are also usually conducted at health centres where better 
treatments are available. Clinical trials are thus not necessarily representative of all cancer 
patients, or of routine healthcare practices in a region or country.20,21 
By contrast, population-based studies of cancer survival provide information about the whole 
cancer population, enabling the assessment of the overall effectiveness of the healthcare 
system on a large-scale basis. All patients diagnosed with cancer while resident in the 
territory covered by the registry are included, regardless of their age, socio-economic status, 
comorbidities, stage at diagnosis or adherence to treatment. This enables population-based 
survival trends to encompass all aspects of the healthcare system: diagnostic efficiency, 




1.7 Aims and objectives 
The aim of this thesis is to obtain complete and reliable data on all cancer patients in Kuwait, 
in order to produce a comprehensive profile of population-based cancer survival, to enable 
the assessment of cancer care in the country. This aim is sub-divided into the following 
objectives: 
• Objective 1: to obtain reliable and complete follow-up data on the last known vital 
status for all Kuwaiti cancer patients registered in Kuwait between 2000 and 2013, 
essential for robust estimation of population-based survival. 
• Objective 2: to estimate net survival up to 5 years after diagnosis for 18 common 
cancers, that can be monitored and compared internationally, in order to facilitate 
the assessment of cancer control strategies. 
• Objective 3: to examine the distribution of stage at diagnosis for 12 cancers in 
Kuwait, and to estimate stage-specific net survival at 1 and 5 years after diagnosis.  
• Objective 4: to evaluate the overall Kuwaiti health care system in managing cancer 




✓ Cancer represents a substantial burden for the Kuwait health care system 
✓ Incidence, survival and mortality need to be examined together to assess 
adequately progress in cancer control in Kuwait.  
✓ Population-based data are required: these data are representative of the 
whole population and are useful to assess the overall health care practices 
in the region. 
What’s next? 





Chapter 2: Literature review 
___________________________________________________________________________________________________ 
2.1 Aim 
The aim of this review is to identify population-based research in Kuwait on incidence, 
survival and mortality that examines one or more of the three main cancer control metrics; 
particularly to identify any studies on cancer survival in Kuwait. 
The search terms and process of the review are set out in Table 2.1 and Figure 2.1. Six 
databases were searched.  
 
Table 2.1 Key topics and search terms for literature review 
Key topics Search terms 
Region (Kuwait*) 
Disease (cancer* OR neoplasm* OR oncol* OR 
tumour OR tumor* OR Leukaemia OR 
Leukemia OR lymph*) 
Outcome (surviv* OR death OR dead OR incidence 
OR mortality) 
 
The review also included abstracts presented at medical conferences, because the 














































*Articles that did not include the key search word “Kuwait” in the title, abstract or keywords 
and were thus not detected in the searches  
892 articles from 6 databases 
144 – EMBASE 
300 – Web of Science 
199 – MEDLINE 
  48 – Global Health 
  13 – CINAHL Plus 
188 – Scopus 
583 articles for abstract 
screening 
309 duplicates excluded 
530 excluded after abstract screening  
  92 – Further duplicates 
  55 – Not about Kuwait 
  44 – Review or comparative study 
    3 – Conference editorials and workshops 
256 – Kuwait but not cancer  
  80 – Cancer in Kuwait - but doesn't include 








49 articles on cancer in Kuwait, 
categorised in 3 groups 
  6 – Not population-based but 
        include cancer metrics 
17 – Population-based but not survival 
26 – Population-based and survival 
 
53 articles for detailed review 
Cancer in Kuwait including 
cancer metrics 
 
7 further exclusions  
3 – Abstracts converted into full articles 
4 – Conference abstracts - no abstract 
      available 
 
Extra inclusions*: 




Figure 2.1 Literature review 
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Eight hundred and ninety-two articles, from 6 data bases, were scrutinised. Duplicates were 
removed and the abstracts screened to exclude articles that were not related to incidence, 
mortality or survival in Kuwait. Further studies were excluded if neither the full text nor the 
abstract was available, or if a conference abstract had subsequently been converted into a 
complete paper. Studies related to Kuwait but not detected by the database search were 
then added. These consisted of international studies that included data from Kuwait but did 
not mention the country in the title, abstract or keywords. Finally, 49 studies relating to 
cancer incidence, survival or mortality in Kuwait, for which at least an abstract was available, 
were reviewed. 
2.2 Studies that are not population-based 
Six studies (3 on incidence22-24 and 3 on survival25-27) only included data from a single 
hospital or a sample of patients for a specific cancer.  
2.3  Population-based studies on cancer incidence and mortality in Kuwait 
Of the population-based studies, 17 involved cancer metrics but did not include survival. 
Two studies reported only the frequencies of lip, oral cavity and pharyngeal cancers28 or 
leukaemia29 in Kuwait between 1979 and 1988. 
Most of the studies reported age-standardised incidence rates (ASIR) for specific cancers: 
nasopharynx,30 lung,31,32 breast,33 pancreas,34 Hodgkin lymphoma,35 non-Hodgkin 
lymphoma,36 and all cases of lymphoma37 for different periods of time, with the most recent 
year of diagnosis in 2012, for pancreas and breast. Cancer incidence rates for all types of 
cancer are presented in the IARC publications: Cancer in Five Continents (CI5), the latest 
volume CI5 XI38 including cancers diagnosed during 2008 to 2012. 
The most comprehensive studies on cancer incidence in Kuwait were produced by the KCR, 
based on data from the annual reports, the most recent published for patients diagnosed in 
2013.39 These studies presented the age-standardised incidence rate (ASIR) for all cancers 
combined for the Kuwaiti population from 1974-2007,40 and 1970-2009.41 The latter study 
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presented ASIR for the ten most common cancers among Kuwaiti males and females. It was 
extended to include forecasting of the expected total number of cancer patients until the 
year 2029. While it is the most comprehensive in terms of types of cancer and the estimates 
produced, it does not include survival. 
Four studies examined mortality due to cancer. One reported the frequency of deaths due 
to cancer in Kuwait in 1989.42 Another study, produced by the KCR, used the death 
information collected by the registry.31 This study presented frequencies of the cancers that 
led to most deaths, the cumulative risk of dying from cancer by the age of 74 years, and the 
age at death due to cancer during 2000-2009 for Kuwaiti nationals. Two studies33,43 used 
mortality data from the Health and Vital Statistics Division at the Department of Statistics 
and Medical Records at the Kuwaiti Ministry of Health. This division produces annual reports 
on mortality rates by sex, age group, nationality and cause of death according to the World 
Health Organization’s International Classification of Diseases, Tenth Revision.44 The first 
study43 compared age-standardised mortality rates (ASMR) due to “neoplasms” for Kuwaiti 
nationals and the total Kuwaiti population in the years 1995 and 2010. The second study33 
presented mortality rates only for breast cancer, with the aim of assessing the impact of 
cancer deaths on life gains in person-years of life, for females in Kuwait. 
IARC’s international study on incidence and mortality, GLOBOCAN, includes model-based 
estimates of incidence rates in 2018, for 185 countries including Kuwait.45 Incidence rates 
for Kuwait were based on retrospective incidence rates, projected forward to 2018, and 
mortality rates were modelled using incidence:mortality ratios derived from neighbouring 
countries. The population used in these analyses were also projected populations for 
Kuwait, and not counts provided by the Department of Health Information and Medical 
Records at the Kuwait Ministry of Health, that were used in the other studies, including the 
CI5 publications. While the GLOBOCAN’s estimation methods have been validated, caution 
is advised against comparing estimates from the recent and previous versions of 
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GLOBOCAN. That is mainly because changes in incidence and mortality rates could be 
partly due to the increasing availability and quality of the incidence data from cancer 
registries worldwide, which is the basis for the modelling methods used to produce the 2018 
estimates.  
Examining trends in incidence and mortality alongside survival trends will enable a more 
comprehensive understanding of the impact of cancer and the progress of cancer control in 
Kuwait.  
2.4 Population-based cancer survival in Kuwait 
Only 26 of the 49 studies published over the 41 years 1978 to 2019 included data on survival. 
All the studies were population-based, using data from the KCR, which collects diagnostic 
information for all cancer patients, but only captures follow-up data on vital status for deaths 
reported as due to cancer.  Eight of the 27 studies on survival were only abstracts of 
research presented in medical conferences. This underscores the scarcity of published 
research on cancer survival in Kuwait. 
Three studies46-48 referred to survival, but did not include formal analyses, only the number 
of deaths or patients’ individual time until death. A number of studies examined survival in 
relation to specific treatment, for cancers of the breast,49-52 oral cavity,53 paediatric54,55 and 
adult Hodgkin lymphoma,56 paediatric57 and adult non-Hodgkin lymphoma,58,59 cervical,60 
uterine,61 rectal,62 renal,63  lung64 and gastrointestinal.58  
In the 16 studies where survival was reported, two presented median survival time,57,64 and 
14 presented overall survival (OS) up to a certain number of years after diagnosis,50,52,54,55,62-
71 i.e. survival for all causes of death combined.  
Median survival summarises the length of time from either the diagnosis or the treatment of 
a disease, to the point at which half of the patients are still alive. In other words, 50% of the 
patients pass away before the median time and 50% live beyond the median time.  
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Overall survival is often referred to as “observed”, “crude” or “all-cause” survival. It is the 
cumulative probability that patients survive a certain period of time after diagnosis, usually 
five years, where the event of interest is death from any cause. No distinction is made 
between causes of death, so these estimates provide a broad view that is not specific 
enough to provide information on surviving a specific cancer. Changes in survival may 
therefore be due either to change in the number deaths from cancer or to change in the 
number of deaths from other causes. Robust comparisons of cancer survival between 
regions or over time cannot be made using overall survival. 
In the 12 studies where statistical methods were indicated, overall survival was estimated 
using the Kaplan-Meier method.72 This method allows the estimation of survival over time, 
even when patients drop out or are studied for different lengths of time.73  
However, overall survival implies surviving any cause of death and not just cancer. In fact, 
all these 12 studies of “overall survival” were based only on deaths reported as due to 
cancer.50,52,54,55,62-67,69,71 Consequently, these studies overestimate the true overall survival, 
because deaths from other causes were not included. 
Even if the intention of these studies was to estimate cause-specific survival (i.e. based only 
on deaths due to cancer), the results remain problematic even if the statistical analysis may 
be appropriate. This is due to the fact that cause-specific survival estimates rely on the 
assumption that no differences or inaccuracies occur in the coding of the underlying cause 
of death between physicians, over time, or between regions. However, due to the variability 
in accurately determining the cause of death between individual physicians, different 
hospitals and countries, cause-specific survival estimates are unreliable within a country or 
region, and not comparable internationally.74-78  
Only one study25 followed up the patients actively to obtain their vital status; however, it was 
not population-based, and only included 47 patients.  
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Seven studies estimated survival where death was not the event of interest,50,55,58,62,65-67,69 
but recurrence or relapse, also called disease-free survival (DFS) or progression-free 
survival (PFS). Overall survival, disease-free survival and progression-free survival are 
measures used within the context of clinical trials and are useful in assessing the effects of 
treatment on cancer outcomes, but they are not relevant to assess the overall effectiveness 
of the health system in curing or prolonging the life of cancer patients following their 
diagnosis. Estimation of “net survival” for all the common cancers, using complete data on 
follow-up for vital status for all patients, and including all causes of death – not just deaths 
due to cancer - would therefore offer a considerable improvement in the quality and 
completeness of information on cancer outcomes in Kuwait [see Section 4.2]. 
2.5 The CONCORD programme 
The CONCORD programme, hosted within the Cancer Survival Group at the LSHTM, is the 
most comprehensive and up-to-date study on global surveillance of population-based 
cancer survival. Its main goals are to compare population-based cancer survival trends 
between countries using standardised quality-control procedures and identical analytical 
methods for all datasets, and to explain the reasons for the differences in cancer survival 
world-wide.  
The first cycle of the CONCORD programme was published in 2008, and included about 1.9 
million adults diagnosed with breast, colon, rectum or prostate cancer in 31 countries. Five-
year population-based survival was estimated for patients diagnosed during 1990-1994, with 
follow-up to the end of 1999.79 In 2015, the second cycle of the CONCORD programme 
(CONCORD-2)80 established global surveillance of cancer survival trends for the first time, 
analysing data for 25.7 million patients diagnosed during the period 1995-2009, with follow-
up to 2009, from 67 countries. CONCORD-2 examined ten common cancers in adults: 
stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, prostate and leukaemia. 
It also examined survival from acute lymphoblastic leukaemia (ALL) in children. 
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The latest cycle of the CONCORD programme, CONCORD-3,81 updated survival trends to 
2014. It included patients diagnosed during the period 2000-2014, with follow-up to 31 
December 2014, from 71 countries and territories. Seven additional cancers were included: 
oesophagus, pancreas and melanoma of the skin in adults (15-99 years), and lymphoma 
and brain tumours in both adults and children (0-14 years). 
The work presented in this thesis enabled collection of complete data on follow-up for vital 
status for all Kuwaiti cancer patients [see Chapter 5]. As a result, Kuwait was able to 
participate in the third cycle of the CONCORD programme.81 This was the first time 


















✓ Ample robust population-based cancer incidence and mortality metrics are 
reported for Kuwait, but not population-based survival. 
✓ Most survival estimates produced for Kuwait rely on vital status data 
obtained through the Kuwait Cancer Registry, which only captures 
information on “deaths due to cancer”.  
✓ Overall survival is estimated for some cancers in Kuwait. However, these 
are likely to be overestimates, because of the unavailability of information 
on deaths due to causes other than cancer. Moreover, these survival 
estimates are not appropriate for comparisons over time or between 
countries. 
What’s next? 
✓ To produce robust net survival estimates for the most common cancers in 
Kuwait, using complete and reliable data on deaths due to any cause, to 










When analysing survival for cancer patients we are interested to know the probability for 
these patients to survive their cancer for a defined period of time since diagnosis. 
When working with data from population-based cancer registries to estimate population-
base survival, the information on cause of death is often unavailable or unreliable. Therefore, 
the goal is to estimate the cumulative probability for cancer patients to survive their cancer 
up to a given time since diagnosis (e.g. 5 years), after accurately controlling for competing 
risk of death (net survival) [section 3.2]. Estimation of survival in the relative survival setting 
[section 3.3] allows estimation of net survival in the absence of accurate information on the 
cause of death. 
3.1  Definition of survival 
Survival analysis is generally used to analyse any data when time to an event is of interest. 
The outcome, therefore, is not based on whether an event occurs or not, but on the time to 
its occurrence. An event can be the patient’s death, the occurrence of the disease, the 
patient’s entry to the hospital etc. The event-time data, also called failure-time or survival 
time, are characterised by a starting point in time (e.g. the date of cancer diagnosis or 
beginning of treatment) and an end-point, defined by the event of interest (e.g. death from 
cancer or death due to any cause), or the end of follow-up. The survival time can be 
measured in days, weeks or years. This type of time-to-event analysis allows patients to be 
“censored”. Censoring occurs when a patient does not experience the event of interest 
during the follow-up time. This could be due to patients being lost to follow-up or due to 
competing events happening prior to the event of interest, or patients who are alive at the 
end of the follow-up. 
The outcome of survival analysis can be expressed as a survival probability or an event rate 




(hazard of death in 
the general 
population) 
certain time (t) since diagnosis. The hazard function is the rate at which an event (usually 
death from any cause) occurs at a specified time since diagnosis. The two measures are 
mathematically related and thus if one is known, the other can be derived.  
 
This formula indicates the relationship between survival and hazard, where S(t) is the 
cumulative survival probability and H(t) is the integrated or cumulative hazard of death. H(t) 
can be calculated as follows, where 𝜆 is the hazard rate i.e. the instantaneous hazard. 
 
In cancer survival analyses, the simplest measure of survival is overall survival (also called 
observed or all-cause survival), in which the event is a patient’s death from any cause. This 
indicator can be useful in a clinical setting, aiding predictive tools and clinical decision 
making.82 However, since patients are subject to several forces of mortality, differences in 
overall survival cannot be attributed solely to cancer. Therefore, to evaluate survival due to 
the actual disease of interest, independent of competing causes, the goal is to estimate “net 
survival”.   
3.2  Net survival 
If cancer is the disease of interest, net survival entails the idea that the overall hazard of 
death for cancer patients is given by the sum of two quantities:  the hazard of death due to 
cancer and the hazard of death due to other causes:    
                       𝜆O                            𝜆P                      𝜆E 
                 Overall hazard      =   competing hazard     +     excess hazard 
            
  
(hazard of death 
in cancer cohort) 
(hazard of death 
due to cancer) 
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Compared to the general population who only experience the background hazard of death, 
for their specific age, sex and calendar year of death, cancer patients have the additional 
hazard of dying due to their cancer. Therefore, the excess hazard (cancer-related hazard) 
can be obtained by removing the competing hazard from the cancer patients’ overall hazard 
of death.  
𝜆E= 𝜆O- 𝜆P  
Net survival is a survival function, derived from the excess hazard (𝜆E) alone.  
The mathematical relationship between the net survival function SE(t), and the excess 
hazard function 𝜆E is shown here:  
 
Net survival can be interpreted as the probability that cancer patients survive their cancer 
up to a specified time (say, five years) since diagnosis, after controlling for competing risks 
of death. 
Net survival derived from data that include all cancer patients diagnosed in a defined region 
(population-based survival), can be used as a measure of the overall effectiveness of all 
aspects of a given health system in managing cancer care. It can be sensitive to changes in 
diagnostic techniques, screening, early diagnostic activities, patterns of care or the efficacy 
of cancer treatments. This indicator, if age-standardised, is also particularly important in 
enabling valid comparisons over time and between sub-populations, and for international 
comparisons, making it a key parameter for epidemiological research and surveillance, and 
valuable for guiding cancer and health policy.20,83,84  
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3.3  Data settings: cause-specific and relative survival 
Net survival can be estimated in two general settings: the cause-specific setting, when the 
exact cause of death is accurately known, or the relative survival setting, when the exact 
cause of death is unknown, unreliable or inaccessible.  
Cause-specific survival relies on information on the underlying cause of death, and uses 
cancer-specific deaths as the event of interest. Deaths due to other causes are censored in 
order to estimate the cancer-specific hazard (excess hazard). The survival for a defined 
calendar period of time can be estimated using standard methods such as the Kaplan-
Meier72 or the actuarial (life table) method.85 
In a relative survival setting, the cause of death is not required for analysis. Therefore, we 
do not need to distinguish whether the patient died from cancer or from another cause. In 
this setting, to estimate the excess hazard of death due to cancer, we need to remove the 
hazard due to causes other than cancer (competing hazard; background mortality in the 
general population) from the overall hazard of death. This entails the assumption that the 
time to death due to cancer and the time to death due to competing causes are conditionally 
independent, given that the patients share the same characteristics (for example same age, 
sex, ethnicity and year of death). The background mortality in the general population from 
which the cancer patients are drawn is assumed to be representative of the hazard of death 
due to causes other than cancer (the competing hazard). This assumption holds because 
deaths specific to each single cancer form a negligible part of the total population mortality.  
The relative survival setting is particularly important when making comparisons of cancer 
survival. The fact that information on the cause of death is not used to derive the excess 
hazard of death due to cancer eliminates any issues related to differences or inaccuracies 




To control for background mortality, we use a set of region-specific life tables of age-specific 
all-cause mortality rates in the general population, stratified by sex and calendar year of 
death, and by other characteristics, such as ethnicity or socioeconomic level when possible. 
The use of life tables in estimating net survival, adjusts for varying levels of background 
mortality between certain populations, regions and over time. This enables survival 
estimates to represent true differences in cancer survival, after correction for background 
mortality between the groups or geographies compared. 
The most recent and unbiased, non-parametric estimator of net survival was proposed by 
Pohar Perme.86 For a cohort of cancer patients, it can be interpreted as the average ratio of 
their overall survival (i.e. survival due to any cause) and the population survival (i.e. survival 




To illustrate this, the instantaneous hazard equation is presented here again: 
                       𝜆O                                  𝜆P                                𝜆E 
                 Overall hazard      =   competing hazard     +      excess hazard 
            
 
The assumption is that the hazard due to causes other than cancer (𝜆Pi) is given by the 
population life tables (background mortality). 
When integrated over time, we have: 
 




Which is equivalent to the excess (net) survival: 
 
And for a cohort of size n, the excess (net) survival becomes 
 
To estimate the net survival, the overall survival probability 𝑆Oi(𝑡) for each individual cancer 
patient (i), and their corresponding expected survival 𝑆Pi(𝑡) if they didn’t have the disease 
(derived from the general population life tables), are compared along time since diagnosis. 
The cumulative net survival 𝑆E(𝑡) is therefore the mean of the individual net survival 
estimates for that cohort of patients. In other words, net survival is a summary of the excess 
hazard (𝜆E) through time and over individuals. 
(hazard of death 
in cancer cohort) 
(hazard of death in the 
general population) 
(hazard of death 
due to cancer) 
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The net survival estimate produced by using the Pohar Perme estimator86 accounts for the 
fact that the risk of death from competing causes is higher in older patients, in other words, 
that the hazard from competing causes increases with age (informative censoring). This 
estimator takes account of this bias using inverse probability weighting, where weights are 
placed on both the cumulative overall hazard and the cumulative competing (population) 
hazard, in order to derive the cumulative excess hazard of death due to cancer. 
To calculate the weights, the general population life tables from which the cancer patients 
are drawn are used. The weights are equal to each individual’s expected survival at a given 
time, i.e. the probability that the patient is still alive at that time if their survival were to be the 
same as the general cancer-free population, given the same demographic characteristics 
(age, sex and year of death). This process of inverse weighting will place a greater weight 
on survival for the elderly, who are progressively more under-represented in the cancer 
cohort with the passage of time since diagnosis, due to their higher risk of competing causes 
of death. This will inflate the number of people remaining at risk to mimic a cohort of patients 
that would have been observed without the effect of competing causes of death (deaths 
other than cancer). Consequently, the bias of informative censoring is dealt with. 
The excess hazard for the entire cancer cohort, from which the cumulative net survival 
estimate is derived, is therefore a weighted average of all the individual patients’ excess 
hazards. 
The Pohar-Perme estimator is considered the gold standard within the relative survival 
setting, because it accounts for informative censoring as well as producing survival 
estimates that are not affected by differences in background mortality. These net survival 
estimates are therefore ideal for comparisons between different populations, geographies 
and over time.87 
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3.4  Design of analysis 
3.4.1 Cohort approach 
In survival analysis, patients need to be followed over time, in order for the event of interest 
to be observed. In cases where all the patients in the cohort are followed for the same 
duration of time, the cohort approach can be used to estimate survival. The cohort approach 
is considered the gold standard85,88 because all patients diagnosed during a specific period 
of time have had the opportunity to be followed for the full follow-up duration (for instance 1, 
5 or 10 years). For example, if we want to estimate 10-year survival for the cancer patients 
included in this thesis [Figure 3.1], the cohort approach can be used for all patients 
diagnosed during 2000-2004, since all patients have a potential follow-up of at least 10 years 
by the end of 2015. Their conditional probabilities of surviving to the end of a given year are 
multiplied within successive calendar years (along the row) to obtain a cumulative probability 
of surviving up to ten years (solid outlines). However, for patients diagnosed during more 
recent periods (2005-2009 and 2010-2013), the cohort approach cannot be used to estimate 
10-year survival, since not all the patients have the full ten-years of follow-up information. 
Other approaches are then required. 
3.4.2 Complete approach 
The complete approach, a variant of the standard cohort approach, can be used when not 
all patients have been followed for the same time, but there is at least one year of diagnosis 
for which patients have had the opportunity to be followed for the entire duration we want to 
analyse. In the same example, the complete approach can be used to estimate 10-year 
survival for patients diagnosed during 2005-2009, even when only patients diagnosed during 
2005 have had the opportunity to be followed for at least ten years by the end of 2015 
(dashed lines). The survival experiences for all the patients diagnosed in the five-year period 
(2005-2009) would be used in the analysis, and patients recently diagnosed would only 
contribute to some of the conditional survival probabilities. Therefore, in addition to 
timeliness, the complete approach has the advantage of efficiently using all the available 
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follow-up data to estimate survival, even though not all the patients have full-term follow-up 
data.85,89 
3.4.3 Period approach 
The period approach provides a short-term prediction of survival for those patients for whom 
follow-up is not available for the required duration, by using the conditional survival 
experience of patients who were diagnosed earlier. For example, the period approach can 
be used to estimate 10-year survival for patients diagnosed during 2010-2013 [Figure 3.1]. 
This entails using the past experience of patients diagnosed between 2000 and 2013, 
conditional on them still being alive at some point during the period 2010-2013 (stippled 
areas). Survival for the 2010-2013 cohort can then be estimated by multiplying the 
conditional probabilities of survival within each calendar year (column) for patients 
diagnosed throughout 2000-2013. For instance, survival during the first year after diagnosis 
is estimated using the survival experience of patients diagnosed during 2010-2013, and 
survival for the second year is estimated from patients diagnosed during 2009-2012, and for 
the third year from 2008-2011, and so forth. The assumption is that the conditional survival 
probabilities observed during 2010-2013 will remain equivalent to the survival probabilities 
observed in each later year, up to ten years since diagnosis. The measure of life expectancy 
at birth also depends on this assumption, where the life expectancy for a baby born today is 
derived from the latest available patterns of mortality for each age and sex.  
Compared to the cohort approach, the period approach better predicts prognosis of recently 
diagnosed patients, for whom full follow-up time is not available. It is also able to detect 
possible changes in survival more promptly than the cohort approach.89-91 




2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2000 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 2000
2001 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 2001
2002 0 1 2 3 4 5 6 7 8 9 10 11 12 13 2002
2003 0 1 2 3 4 5 6 7 8 9 10 11 12 2003
2004 0 1 2 3 4 5 6 7 8 9 10 11 2004
2005 0 1 2 3 4 5 6 7 8 9 10 2005
2006 0 1 2 3 4 5 6 7 8 9 2006
2007 0 1 2 3 4 5 6 7 8 2007
2008 0 1 2 3 4 5 6 7 2008
2009 0 1 2 3 4 5 6 2009
2010 0 1 2 3 4 5 2010
2011 0 1 2 3 4 2011
2012 0 1 2 3 2012
2013 Period analysis (stippled) 0 1 2 2013
Follow-up
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Figure 3.1 Cohort, complete and period approaches to survival estimation 
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3.5 Age standardisation 
Age-standardisation is vital when comparing net survival estimates for all ages combined, 
because net survival can vary considerably by age, and the age structure of cancer patients 
differs between countries and over time. Therefore, comparisons between un-standardised 
cancer survival estimates for all ages combined between countries or over time are 
inappropriate.  
In order to produce age-standardised survival estimates, age-specific survival estimates are 
required for each age group. The age-specific weights recommended for cancer survival 
analyses are is the International Cancer Survival Standard (ICSS) weights,92 derived from a 
population of cancer patients rather than the general population. Three sets of weights 
probabilities provided depend on the type of cancer. The first set is for cancers where the 
incidence increases rapidly with age, such as lung. The second, for cancers like brain, that 
usually peak in the younger and older ages but are less common in the middle-age-groups, 
while the third is for cancers such as Hodgkin’s lymphoma that are more common among 
the young.  
To produce age-specific estimates for each cancer, age at diagnosis is categorised into 5 
groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. For prostate cancer, 5 different age 
groups are used: 15-54, 55-64, 65-74, 75-84 and 85-99 years. The age-specific survival 
estimates are then multiplied by the corresponding age-specific weights, to represent age-
specific estimates that are proportionate to the standard population. The age-standardised 
survival estimate for all age groups combined is then given by the weighted average of the 
age-specific survival estimates.  
Using the same sets of weights when comparing age-standardised estimates over time or 
between different regions ensures that differences are not due to different weights, and that 
differences in the age-structure of the cancer patient groups being compared will not 





















✓ Population-based survival (net survival) is a key indicator to evaluate 
the overall effectiveness of the health system in managing cancer. 
✓ To estimate net survival, the relative survival setting is preferred, 
since it does not require information on the cause of death. 
✓ Different designs of analysis are used depending on the purpose and 
availability of follow-up data.  
✓ Complete and reliable data on follow-up for vital status, that includes 




✓ How do we obtain complete data on follow-up for vital status for all 





Chapter 4: Research paper I; Obtaining data on follow-up 
for vital status 
___________________________________________________________________________________________________ 
 
Monitoring survival, alongside incidence and mortality, is essential when assessing progress 
in cancer control.16 In Kuwait, incidence and mortality are routinely produced and monitored 
but population-based survival estimates are not. This is mainly due to the unavailability of 
complete information on vital status for all cancer patients. 
In order to produce robust population-based net survival estimates, it is necessary to have 
the full date (day, month and year) of both the cancer diagnosis and the last known vital 
status for all patients. When the patient has died, the date of death is required, regardless 
of the cause of death.93 
Complete and high-quality information on cancer diagnosis is available from the Kuwait 
Cancer Registry (KCR). However, with respect to vital status information, the KCR is only 
able to capture cancer patients’ deaths if the cause was attributed to caner. Cancer patients 
whose death was certified as attributable to other causes are not reported, and those 
patients are, in effect, “immortal” in the registry’s database. 
The following chapter completes the first objective of the thesis: to obtain accurate and 
complete follow-up data on the last known vital status for all Kuwaiti cancer patients 
registered in Kuwait between 2000 and 2013. This is essential for robust estimation of 
population-based survival. 
This objective was achieved through the implementation of a new approach, performed in a 
series of semi-manual steps, since records are not yet electronically linked. The first step 
was to obtain government-issued Civil ID numbers (IDs) of patients registered during 2000-
2013 from the Kuwait Cancer Registry. The second step involved both electronic and 
manual tracing of missing IDs using the Ministry of Health’s Information System or via the 
patient’s medical records. If patients’ IDs were not available following these tracing 
44 
 
procedures, the vital status for the patients was recorded as “lost to follow-up”. The third 
step was to update the vital status for patients whose vital status was not known in the 
registry. This was performed by manually entering the IDs in the Public Authority of Civil 
Information (PACI) database, to ascertain whether the patient was dead or alive. To obtain 
the date of death for the deceased patients, IDs were then manually entered and searched 
in the electronic archive of “Death Announcements” at the Ministry of Health’s Central 
Records Department of Births and Deaths. Patients not found to be dead were considered 
alive as on 31 December 2015. 
Unlike the traditional method used by the registry, this new approach enabled ascertainment 
of cancer patients’ deaths due to any cause, not just deaths due to cancer. It was shown to 
be highly effective, resolving the vital status and, if dead, the date of death, for almost all 
(98.3%) patients whose vital status had previously been unknown; remarkably improving the 
quality of the cancer patients’ vital statistics and enabling net survival analyses to be 
performed for the first time. 
It was due to work presented in the following paper that made this possible for the Kuwaiti 
data to be included in the third cycle of the CONCORD programme for global surveillance 








Research paper I [published]  
A novel approach to obtain follow-up data on the vital status of 




Cancer is the second most common cause of death in Kuwait, following diseases of the 
circulatory system.94 Reducing cancer-related deaths can be achieved primarily in two ways: 
by reducing cancer risk, or by improving the health-care system in terms of management 
and treatment of cancer patients.83 Population-based cancer survival is a key measure of 
the effectiveness of a health system in managing cancer.83,84 Monitoring survival over time, 
between sub-populations and between countries, is also crucial for assessing inequalities 
and driving policies for cancer control.21,95 
The aim of population-based survival analysis is to estimate net survival for all cancer 
patients diagnosed in a given region over time. Net survival represents the cumulative 
probability for cancer patients to survive their cancer up to a given time (say, 5 years) since 
diagnosis, after controlling for competing risks of death (background mortality).86 Net survival 
can be measured in two contexts: a cause-specific setting, when the exact cause of death 
is known and accurately reported, or a relative survival setting, when the exact cause of 
death is unknown, unreliable or inaccessible.  
Cause-specific survival estimation requires information on the underlying cause of death, 
and uses as an end-point those deaths that were attributed to cancer. Patients who die from 
other causes are censored, in order to estimate the cancer-specific hazard of death (excess 
hazard). This approach relies on the assumption that the death certification and the coding 
of the underlying cause of death are accurate.  However, due to the variability in determining 
the cause of death accurately between physicians, hospitals, and countries, cause-specific 
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survival estimates are not considered suitable for comparisons between countries or over 
time.74,75,77 
The procedure for coding the underlying cause of death also differs between countries. For 
example, the procedures are different in Kuwait and the United Kingdom (Figure 4.1). In 
Kuwait, the “Death Announcement” is similar to the Medical Certificate of Cause of Death 
(MCCD) used in the UK,96 which includes a section on the cause of death. Both are 
completed by physicians or hospital authorities, in accordance with the World Health 
Organisation (WHO) recommendations in the International Statistical Classification of 
Diseases and Related Health Problems (ICD).97 However, the categories used to report 
cancer as the underlying cause of death differ in the two countries (Figure 4.1). The Kuwait 
Cancer Registry (KCR) reports the cause of death as “due to cancer” if either the first line 
(a) of the Death Announcement (the so-called “immediate cause” of death) or the third and 
last line (c) of the Death Announcement (the so-called “original or underlying cause” of 
death) is a cancer-related condition. The second line (b) of the Death Announcement is not 
coded, and will not be considered as the underlying cause of death even if the last line is 
not completed. In the UK, all three lines (Ia, Ib, Ic) of the sequence of events leading to death 
on the MCCD are taken into account to determine the underlying cause of death. This 
difference in coding the underlying cause of death may lead to under-estimation of cancer 
mortality rates in Kuwait, compared to the UK. Even minor misclassifications of the 
underlying cause of death have been shown to result in large changes in net survival 
estimates.98 In addition, cause-specific estimates tend to be higher than relative survival 
estimates,98,99 therefore overemphasising the effectiveness of the health system in dealing 
with cancer.  
Estimating cancer survival within a relative survival framework eliminates any differences or 
inaccuracies in certifying or coding the underlying cause of death, because the cause of 
death is not required for analysis. Relative survival is estimated as the ratio of the cancer 
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patients’ all-cause survival, where the endpoint is death from all causes, to the survival that 
the patients would have experienced if they had had the same background mortality as the 
general population (expected survival).85,100 Expected survival is estimated from population 
life tables that adequately represent the all-cause mortality experience of the population 
under study.101-103 The relative survival framework is more appropriate for the estimation and 
comparison of net survival.81,98,104,105 
To produce reliable and accurate population-based survival estimates, it is necessary to 
have complete, reliable and long-term data for all patients diagnosed with cancer in a defined 
geographical area. It is thus imperative to have accurate and complete data on the date of 
diagnosis, the last known vital status and the date of last known vital status. When the patient 
has died, it is essential to know the date of death, regardless of the cause.  
Many countries are able to maintain long-standing, high-quality population-based cancer 
registries and provide accurate incidence data. However, it is becoming increasingly difficult 
to obtain follow-up data and ascertain complete vital status for all patients. Many countries, 
including high-income countries such as Canada and Saudi Arabia, have reported difficulties 
in accessing this information for all cancer patients, due to technical, legal or administrative 
barriers.81 A recent international meeting on strengthening the health system and breast 
cancer care in the Middle Eastern countries, organised by the Harvard Medical School 
Center for Global Health Delivery in Dubai,106 highlighted the fact that even in high-income 
Middle Eastern countries, efficient civil registration and availability of unique identification 
codes, both crucial to obtain the data on follow-up for vital status, are still problematic. Such 
difficulties hinder robust survival estimation and, in many cases, prevent survival estimates 
from being produced at all. 
An example of a national population-based registry that maintains high-quality cancer 
incidence data for the whole country is the Kuwait Cancer Registry (KCR), a department of 
the Kuwait Cancer Control Centre (KCCC).107 However, complete data on vital status for all 
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registered cancer patients are not available, since the registry has only been able to capture 
information on deaths due to cancer. 
This study presents a novel approach to obtain accurate and complete follow-up data on the 
last known vital status and the date of last known vital status, as on 31 December 2015, of 
all Kuwaiti cancer patients registered between 2000 and 2013, thus enabling robust 
estimation of population-based survival in Kuwait. 
Materials and Methods 
Data on 12,469 patients diagnosed during 2000-2013 were obtained from the KCR 
database, including the patient’s hospital file number, the Civil ID number where available, 
and the date of diagnosis (Figure 4.2, step 1). The Civil ID number was missing for 2,026 
patients, and it was necessary to obtain these numbers, either electronically from the Health 
Information System or manually through the medical records (Figure 4.2, step 2), so that the 
records for all patients could then be manually linked with the Public Authority of Civil 
Information (PACI) database. The PACI database is considered to be the most reliable and 
up-to-date source to obtain the last known vital status, and the date of last known vital status, 
of any person resident in Kuwait, provided that their Civil ID number is known.  
Only Kuwaiti patients were included in this study, since vital status information for non-
Kuwaitis is relatively incomplete. Non-Kuwaiti residents are mostly expatriate labourers 
employed with short contracts (e.g. two-year contracts) who generally choose to return 
home upon completion of their contracts or when they become terminally ill. Although the 
vital status (alive or dead) of non-Kuwaitis in Kuwait is also recorded in the PACI database, 
it cannot be used to track the vital status of persons who have left the country. Therefore, 





Tracing of Civil ID numbers 
To obtain the Civil ID number for Kuwaiti patients for whom it was not available, an 
“electronic search” using the patient’s hospital file number was queried from the Health 
Ministry's Health Information System (HIS) database.  If the Civil ID number was not 
available in the HIS system, a “manual search” was performed: the patient’s hospital file 
number was used to locate and check the physical medical file in the Medical Records 
Department at the KCCC, in order to identify the Civil ID number of each patient. This step 
was performed twice (once at the beginning of this tracing process and once after 6 months), 
to increase the prospect of locating patients’ files that might previously have been misplaced.  
If the Civil ID number could not be traced, but a date of last known vital status earlier than 
31 December 2015 was available in the medical records, this date was extracted to update 
the database. These patients were considered lost to follow-up and will contribute to survival 
analysis until that date. 
Vital status and date of last known vital status update 
To obtain follow-up data on last known vital status and date of last known vital status, a list 
of Civil ID numbers, sorted by year of diagnosis, was printed. Direct linkage with the PACI 
database was not permitted, therefore indirect access was granted through the Central 
Records Department of Births and Deaths at the Ministry of Health. Employees from this 
Department who have access to the PACI database manually entered the Civil ID numbers 
to determine each patient's vital status. If the patient was alive, the employee recorded the 
status as “alive” on the printed sheet. If the patient was dead, the employee used the 
patient’s Civil ID number to access the Central Records Department’s computerised 
database in order to obtain the exact date of death from the electronic archive of “Death 
Announcements”, which is updated on a continuous basis. Each cancer patient’s updated 
vital status was then entered manually into our existing cancer dataset, matched to the 
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patient’s record with the corresponding Civil ID and file numbers. The vital status was 
recorded as alive at 31 December 2015 for patients who were alive, or dead, with the date 
of death, for deceased patients. 
Quality control 
To ensure the correct transfer of vital status data from hard copy to the electronic database, 
data entry was verified by checking every 10th record on the hard copy with the vital status 
data that had been entered. This process was performed on all the records that had been 
linked with the PACI database, and errors were corrected. All dates of death entered 
manually were also double-checked, to ensure correct transfer from the hard copy to the 
electronic database.   
Results 
During 2000-2013, Civil ID numbers were available in the registry for 10,443 (83.7%) of 
12,469 Kuwaiti cancer patients registered (Table 4.1; Figure 4.2, step 1). Among these 
patients, 2,781 were known to be “dead”, with the cause of death attributed to cancer, while 
the vital status was unknown for the remaining 7,662 patients (61.4%). 
The Civil ID number was not available for 2,026 patients (16.3%). Of these, 694 were known 
to be dead due to cancer, while the vital status of the remaining 1,332 (10.7%) patients was 
not known and needed to be traced and updated. 
Most of the patients with unknown vital status and without Civil IDs had been diagnosed 
during 2000-2004; the proportion dropped from 35.4% to 0.5% for those diagnosed during 
2010-2013 (Table 4.2; Figure 4.2, step 2). This combination of manual and electronic search 
enabled tracing of 1,175 out of 1,332 Civil ID numbers; 157 Civil ID numbers remained 
unavailable. However, for these patients, a date of last known vital status earlier than 31 
December 2015 was available from the medical records. Therefore, these patients were 
considered lost to follow-up at that date. The overall proportion of patients without a Civil ID 
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who would be considered lost to follow-up decreased from 10.7% to 1.3%. The impact of 
this tracing was most marked for patients diagnosed during 2000-2004, among whom the 
percentage whose Civil IDs were not available fell from 35.4% to 3.7%. 
Tracing the Civil ID numbers enabled the vital status to be reliably ascertained through the 
PACI database, and updated for 8,837 (98.3%) of 8,994 of patients for whom it was initially 
unknown (Table 4.3; Figure 4.2, step 3). As a result, the number known to be dead rose by 
2,131. The proportion of total deaths increased from 27.9% (3,475 patients, of which 2,781 
had Civil ID numbers and 694 did not) to 45.0% (5,606 patients, including 3,475 known to 
be dead due to cancer and 2,131 known to be dead due to other causes). About 54% (6,706) 
out of the 12,469 patients were shown to be alive, leaving only 157 classified as lost to 
follow-up. 
Discussion  
We present a novel approach to obtain complete follow-up data on the vital status of all 
Kuwaiti cancer patients. This approach enabled us to update the vital status for most (98.3%) 
Kuwaiti cancer patients registered during the period 2000 to 2013.  
Of the deaths occurring by 31 December 2015 among cancer patients registered during 
2000-2013, only 62.0% (3,475 of 5,606) had initially been recorded in the KCR database 
through the traditional follow-up method, relying solely on deaths that had been certified as 
due to cancer. 
The process of tracing Civil ID numbers enabled ascertainment of the vital status for almost 
all registered cancer patients, including all deaths, regardless of the cause. This had a 
substantial impact on the proportion of cancer patients who were known to be dead, which 
rose from 27.9% to 45.0%, while the proportion considered to be alive at the end of follow-
up dropped from 72.1% to 53.7%.   
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The most evident changes resulting from tracing the Civil ID numbers occurred during 2000-
2004, where the proportion of patients without Civil IDs and with unknown vital status was 
much greater (52.5%) than in 2005-2009 (3.1%) and in 2010-2014 (1.1%). This difference 
was probably due to several improvements in KCR registration practices, implemented over 
the years: the routine practice of obtaining the patients’ Civil ID during registration was 
progressively enforced, resulting in lower numbers of patients without ID numbers. The 
availability of Civil IDs is crucial to the implementation of our approach: a higher proportion 
of IDs made linkage between the cancer registry data and the patients’ vital status records 
more effective. Complete and accurate data on follow-up for vital status are essential to 
enable robust estimation of population-based cancer survival.  
Observed survival (also called all-cause survival) can be useful in predictive tools and cost-
effectiveness analyses,82 but it cannot be used to provide information on the probability of 
surviving a specific cancer, or to examine cancer survival trends within a given country, 
because its estimation also includes deaths from causes other than cancer (competing risks 
of death), which are likely to be decreasing over time due to continuous medical 
advancement. Similarly, observed survival estimates cannot be used for international 
comparisons of cancer survival, since background mortality also varies very widely between 
countries.103,108,109 Estimates of observed survival can also substantially over-estimate the 
true observed survival if based only on deaths that were certified or coded as due to cancer, 
because deaths from causes other than cancer are not included in the computation.  
The accuracy of death certification and of the coding of the underlying cause of death can 
vary between countries and over time within a country. These can arise from inaccuracies 
in the certification of death when compared with autopsy findings and clinical data, 
differences among physicians in completing the death certificates, and variations in coding 
the underlying the cause of death.74,75,77 Inaccuracies in certifying the cause of death have 
been found in Kuwait when original death certificates were compared with the patients’ 
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medical records, indicating poor agreement in the certification of death between the original 
and revised certificates.110 
Other differences in death registration practices can arise from changes to the death 
certificate forms used in a country, when coding rules are updated or revisions of the ICD 
are introduced, from changes in diagnostic terminology and measurement, or when there is 
a lack of training in certifying the cause of death.111-113 
For all these reasons, international comparisons of population-based cancer survival require 
statistical methods that do not rely on the cause of death (net survival). By eliminating the 
effect of background mortality, differences and trends in net survival reflect differences in 
cancer outcome, rather than differences in competing causes of death. Net survival 
estimates are thus better suited for international comparisons and to evaluate the impact of 
changes in health policy over time. 
Our approach to obtain follow-up data through individual record linkage between the KCR 
database and the PACI database provides the most complete and up-to-date information on 
the vital status for almost all Kuwaiti cancer patients. However, to conduct this update 
manually is labour-intensive and time-consuming, and requires extensive quality checks on 
the manual entry and extraction of data. If performed efficiently, electronic linkage between 
the cancer registry database and the vital status data stored in the PACI database would be 
more accurate and timely, but it is more complex and requires ministerial agreement and 
collaboration.   
The use of this novel approach will provide the Kuwait Cancer Registry with more accurate 
and complete information on Kuwaiti cancer patients’ vital status, on a routine basis.  It will 
allow clear distinction between patients who are alive and patients who are dead from any 
cause (i.e. not just those who have died from cancer). These data, together with the use of 
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appropriate life tables of background mortality, would enable Kuwait to monitor routinely net 
survival trends and to compare cancer survival in Kuwait with survival in other countries. 
Conclusion  
Robust estimates of population-based cancer survival are crucial to assess the effectiveness 
of the health system in managing cancer. Complete and reliable data on follow-up for vital 
status of all cancer patients, regardless of the cause of death, are essential to produce 
robust cancer survival estimates that can be monitored over time and compared 
internationally.  
Prior to this study, there was no system to update the vital status for all Kuwaiti cancer 
patients. With support from the Kuwait Ministry of Health and the Ministry of Interior/PACI 
this approach could be performed routinely by the KCR to ensure (a) that virtually all deaths 
of Kuwaiti cancer patients, regardless of the cause, are systematically recorded; and (b) that 
the follow-up on the vital status of all cancer patients is accurately updated through record 
linkage between the KCR database and the PACI database. The ultimate goal would be to 
establish routine electronic linkages with the PACI system, making the process more 
efficient and timely.  
Several countries in the Gulf Cooperation Council (e.g. Qatar, Bahrain and United Arab 
Emirates) have an administrative system similar to the one in Kuwait. This study may assist 
cancer registries in these countries to integrate the conceptual framework in their 
administrative system, to improve their follow-up procedures and to enhance the quality of 





Figure 4.1 An example of the “cause of death” sections of the UK’s Medical 
Certificate of Cause of Death (MCCD) and of the Kuwait Death Announcement, used 
to determine the underlying cause of death 
Medical Certificate of Cause of Death in the UK 
Cause of death the disease or condition thought to be the underlying cause should 
appear in the lowest completed line of part I 
I  (a) disease or condition leading directly to death  Intraperitoneal haemorrhage  
 (b) other disease or condition, if any, leading to I(a)  Ruptured metastatic deposit in 
liver 
 (c) other disease or condition, if any, leading to I(b)  Primary adenocarcinoma of 
colon  
 
II  Other significant conditions contributing to death 
but not related to the disease or condition causing 
it  
Non-insulin dependent 
diabetes mellitus  
 
Death Announcement in Kuwait 
Deaths in less than a week old children Deaths in more than a week olds 
(a) Basic disease or condition 
 in child     
(a) Immediate cause: Intraperitoneal  
         Haemorrhage K 6 6 1 
(a) Other disease or condition in child (b) Secondary cause: Ruptured  
metastatic deposit in liver 
(b) Disease or condition in mother   
 that led to child’s death      
(c) Original/ Underlying cause:  
Primary adenocarcinoma of 
colon 
C 1 8 9 











Table 4.1 Number of Kuwaiti cancer patients, with and without Civil ID numbers, by 
period of diagnosis 
  
 
Table 4.2 Kuwaiti patients with unknown vital status and Civil ID numbers not 







Unknown vital status: patients not reported as dead due to cancer 
 










* These patients were presumed alive (not known to be dead) in the KCR before applying our approach to update the follow-
up data  
No. % No. % No. % No.    %
All patients 3,489 4,545 4,435 12,469
Civil ID number available 1,656 47.5 4,402 96.9 4,385 98.9 10,443 83.7
         Dead (due to cancer) 496 14.2 1,400 30.8 885 20.0 2,781 22.3
         Unknown vital status 1,160 33.3 3,002 66.1 3,500 78.9 7,662 61.4
Civil ID number not available 1,833 52.5 143 3.1 50 1.1 2,026 16.3
         Dead (due to cancer) 597 17.1 69 1.5 28 0.6 694 5.6
         Unknown vital status 1,236 35.4 74 1.6 22 0.5 1,332 10.7
Calendar period of diagnosis
         2000-04 2005-09 2010-13   All periods
  Pre-update   Post update   
Vital Status No. %   No. %   
Dead (due to 
cancer) 
3,475 27.9   - -   
Dead (due to any 
cause) 
- -   5,606 45.0   
Alive - -   6,706 53.7   
Lost to follow-up - -  157 1.3  
Unknown* 8,994 72.1   - -   
Total 12,469 100.0   12,469 100.0   
       
No. % No. % No. % No.    %
Unknown vital status
Before Tracing
Civil ID number not available  1,236 35.4 74 1.6 22 0.5 1,332 10.7
After tracing 
Civil ID number traced 1,107 31.7 49 1.1 19 0.4 1,175 9.4
Civil ID number not available 129 3.7 25 0.5 3 0.1 157 1.3
Calendar period of diagnosis
2000-04 2005-09 2010-13   All periods
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Chapter 5: Research paper II; Population-based cancer 
survival in Kuwait 
___________________________________________________________________________________________________ 
 
To produce robust population-based net survival estimates, complete and accurate data are 
required on the date of cancer diagnosis, the last known vital status and, for those patients 
who have died, the date of death, irrespective of the cause. To estimate the survival of all 
patients diagnosed with cancer in a given population is crucial to assess the overall 
effectiveness of the health-care system in managing cancer. One of the goals of the 2013 
World Cancer Declaration is to achieve worldwide improvement in cancer survival by 2020. 
In order to achieve this goal, routine measurement and monitoring of survival is imperative.  
Through the work presented in Chapter 5, complete and reliable data on follow-up for vital 
status were obtained for all Kuwaiti patients registered in the Kuwait Cancer Registry during 
2000-2013. This was the first time such data had become available, providing Kuwait with 
the first population-based 5-year net survival estimates for Kuwaiti patients diagnosed with 
one of 18 common cancers during 2000-2013. It also enabled Kuwait to participate in the 
third cycle of the CONCORD programme on the global surveillance of cancer survival.81 
In the following chapter, I proceed to use the CONCORD programme protocol and data 
quality control procedures, as well as the same design of analysis and statistical methods, 
to extend the analyses, to produce population-based survival estimates at 1, 3 and 5 years, 
and to monitor survival trends over 14 years, for three calendar periods (2000-2004, 2005-
2009 and 2010-2013) and sex. 
The inclusion of this dataset in the CONCORD programme has allowed appropriate 
comparisons between Kuwait and 70 other countries also included in CONCORD-3. The 
emphasis, however, was placed mainly on comparisons between Kuwait and other high-
income countries, where discrepancies in survival were noted and discussed. 
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This chapter fulfils the second objective of my thesis: to produce net survival estimates for 
Kuwait that could be monitored and compared internationally, in order to facilitate the 









Research paper II [published] 




Cancer is the second most common cause of death in Kuwait, after cardiovascular 
diseases.94 To evaluate the effectiveness of health systems in controlling the cancer burden 
and preventing cancer-related deaths, three population-based metrics need to be assessed: 
incidence, survival and mortality.16 Population-based metrics are obtained using data on all 
cancer patients residing in a defined geographic area. These data are collected by 
population-based cancer registries. While trends in cancer incidence and mortality are 
routinely monitored in Kuwait, population-based cancer survival trends are not. 
Because survival time is dependent on two events, diagnosis and death, complete data on 
the eventual death of all cancer patients, regardless of the cause of death, are required to 
produce reliable and accurate survival estimates.80 Producing population-based cancer 
survival estimates from complete and good-quality data for Kuwait is important for several 
reasons. Firstly, population-based survival represents a reliable measure for assessing the 
effectiveness of all aspects of the health system, from awareness and diagnosis to the 
system’s ability to treat and cure cancer. Age-standardised survival estimates are essential 
for making valid comparisons over time, between sub-populations and countries, to guide 
cancer control policies.83 To understand progress against cancer fully, therefore, it is 
essential to assess survival estimates alongside incidence and mortality.  
This study aims to produce a comprehensive profile of population-based cancer survival in 
Kuwait: robust estimates of net survival up to 5 years for 18 common cancers that can be 




Material and methods 
The data used in this study were obtained from the Kuwait Cancer Registry (KCR). Cancer 
notification in Kuwait is mandatory by ministerial regulation. The KCR is considered to be a 
comprehensive source of information for all cancer patients diagnosed or treated in Kuwait. 
Kuwait incidence data on patients diagnosed since 1979 have been published in "Cancer 
Incidence in Five Continents",114 which is generally considered an imprimatur of high-quality 
data.  
The KCR maintains an index of all cancer patients through collecting information on 
malignant neoplasms according to the International Association of Cancer Registries (IACR) 
guidelines (www.iarc.fr).  Since January 2000, the registry has adopted the third edition of 
the International Classification of Diseases for Oncology (ICD-O-3)115 for all clinical coding, 
including topography, morphology and behaviour.  
Data were obtained for Kuwaiti adults (age 15-99 years) and children (age 0-14 years) 
diagnosed between 1 January 2000 and 31 December 2013 with one of 18 cancers or 
groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast 
(women), cervix, ovary, prostate and melanoma of the skin in adults, together with brain 
tumours, leukaemias and lymphomas in both adults and children.  
Data were collected according to the CONCORD protocol.81 Topography and morphology 
were coded to the International Classification of Diseases for Oncology (third edition, ICD-
O-3),115 including its first revision.116 Solid tumours were defined by anatomical site 
(topography), while leukaemias, lymphomas and melanoma of the skin were defined by 
morphology (Table 5.1). 
The KCR provided data for all haematopoietic malignancies (ICD-O-3 morphology codes in 
the range 9590-9992) in adults and children. For adults,  we analysed “lymphoid 
(HAEMACARE groups 1-19)” or “myeloid (HAEMACARE groups 20-25)” malignancies, in 
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consultation with specialists in the HAEMACARE117 and InterLymph118 working groups 
(Table 5.2). For children, we analysed survival for acute lymphoblastic leukaemia (ALL) and 
lymphomas, based on the International Classification of Childhood Cancer 3rd edition (ICCC-
3)119 (Table 5.3).  
Only primary, invasive malignancies (ICD-O behaviour code 3) were included in survival 
analyses. The only exception was brain tumours, where tumours of benign or uncertain 
behaviour (code 0 or 1) were also included (Table 5.4). Other ineligibilities included records 
that were incomplete or outside the age range specified in the CONCORD protocol, as well 
as tumours that were metastatic from another primary site, or were unknown whether 
primary or metastatic.  
Follow-up data on each patient’s vital status (alive, dead, lost to follow-up), at 31 December 
2014, were obtained through a mixture of passive and active methods, to include all deaths 
regardless of the cause of death. Passive follow-up is the term used when cancer registries 
routinely receive notification of deaths from a vital statistics office, or when they link cancer 
registrations to vital statistics records at routine intervals, using unique identifiers such as 
name or identity numbers. Active follow-up refers to the process whereby a registry actively 
seeks data on the vital status for each patient via direct contact with hospitals, the patient’s 
family or local authorities.80,120 The follow-up procedures in this study involved a series of 
steps that included identifying the unique national identification numbers (Civil ID numbers) 
of all the Kuwaiti patients, and manually linking them to the country’s centralised registration 
database, the Public Authority of Civil Information (PACI). This provided accurate 
information on all deaths, irrespective of whether the cause of death was cancer-related. 
The dates of death for deceased patients were obtained by manual search of the Civil ID 
numbers from the electronically archived “Death Announcements” at the Central Records 
Department of Births and Deaths. In cases where the patient’s vital status could not be 
ascertained, the date when the patient was last known to be alive was extracted from the 
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patient’s medical hospital files: the tumour registry record was updated, the vital status was 
recorded as “lost to follow-up”, and the patient was censored from analysis at the date he or 
she was last known to be alive. 
Quality control 
Quality and completeness were assessed using the standardised quality-control procedures 
from the CONCORD programme for global surveillance of cancer survival.81 
The data quality checks were performed in three consecutive phases. Phase one, protocol 
adherence, examines each individual variable within a given record for compliance with the 
CONCORD protocol. Phase two, exclusions, assesses logical coherence between the 
variables in each tumour record, and excludes records, such as tumours known to the 
registry only from a death certificate, or detected solely through autopsy. These records 
must be excluded from survival analyses since follow-up time is not available. Other 
exclusions are related to records with vital status unknown, or an invalid date sequence, or 
inconsistencies between sex and site, site and morphology, age and site, or age and site 
and morphology.  
Duplicate registrations were also excluded. When two or more primary, invasive 
malignancies with the same site existed in the same person and the records had the same 
date of diagnosis, the record with the most complete information was retained. If these 
records presented different dates of diagnosis, the record with the earliest date of diagnosis 
was retained.  
Phase three, editorial, evaluates, for each cancer, the distribution of key data quality 
indicators. Table 5.4 provides a summary of the records that were excluded from survival 
analysis, and the number of patients included in analyses, together with the distribution of 




We estimated net survival for patients diagnosed with one of 18 malignancies during 2000-
2004, 2005-2009 and 2010-2013. Survival was estimated at 1, 3 and 5 years after diagnosis, 
for males, females and both sexes combined.  
For patients diagnosed in 2000-2004 and in 2005-2009, for whom follow-up was available 
for the full duration of the survival analysis (either one, three or five years), estimates were 
produced using the cohort approach. The cohort approach is considered the gold standard,88 
because it provides a survival estimate for a cohort of patients who were all diagnosed during 
the same year or calendar period and followed up for at least the duration for which survival 
estimates are required, in this case 1, 3 or 5 years. For 2010-2013, we applied the “period” 
approach,90 which offers reliable prediction of the eventual survival of recently diagnosed 
patients who have not all been followed up for the whole time of analysis. 
Net survival is the term used to describe the probability that cancer patients survive their 
cancer up to a given time (e.g. five years) following diagnosis, after controlling for competing 
causes of death (background mortality).121 To control for background mortality, we used life 
tables of all-cause mortality in the general population.103 Life tables were constructed by 
single year of age (“complete” life tables), sex, calendar year of death and ethnicity (Kuwaiti, 
non-Kuwaiti).  
To estimate net survival, we used the Pohar-Perme estimator,86 implemented with the 
program stns122 in Stata version 14 (StataCorp LP, College Station, TX). This estimator 
accounts for the fact that competing risks of death are higher in older cancer patients.  
For each cancer, calendar period and sex, we present age-standardised net survival 
estimates for up to 5 years after diagnosis. For adults, we used the International Cancer 
Survival Standard (ICSS) weights,92 in which age at diagnosis is categorised into 5 groups: 
15-44, 45-54, 55-64, 65-74 and 75-99 years and, for prostate cancer, 15-54, 55-64, 65-74, 
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75-84 and 85-99 years. Of the three sets of ICSS weights, we used group 2 (cancers for 
which incidence does not increase steeply with age) for melanoma of the skin, cervix uteri 
and brain (adults), and group 1 (cancers for which incidence does increase steeply with age) 
for oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast, ovary and prostate, 
and both groups of haematopoietic malignancies. For children, we estimated survival for the 
age groups 0-4, 5-9 and 10-14 years; age-standardised estimates were obtained by 
assigning equal weights to the three age-specific estimates.123,124 Cumulative survival 
probabilities in the range 0-1 are presented for convenience as percentages in the range 0-
100%. 
Survival was not estimated if fewer than ten patients were available for analysis. When the 
total number of available patients was fewer than 50, unstandardised estimates were 
produced for all ages combined. When the number of patients was 50 or more, age-specific 
estimates were produced where possible and an age-standardised summary estimate was 
derived. Where an age-specific estimate could not be obtained, the data from adjacent age 
groups were merged, and a combined estimate was assigned to both age groups. If two or 
more age-specific estimates could not be produced, only the unstandardised estimates for 
all ages combined were presented. 95% confidence intervals (CI) for both unstandardised 
and standardised survival estimates were derived assuming a normal distribution, truncated 
to the range 0-100. Standard errors to construct the CIs were calculated using the 
Greenwood method.125 If no death or censoring occurred within 5 years, or if all patients died 
within 5 years (survival probability 1 or 0), we obtained a binomial approximation for the 
lower or upper bound respectively, of the CI.  
Results 
Of 8,931 tumour records for adults (8,477) and children (454) diagnosed during 2000-2013, 
8,484 (95.0%) were included in the survival analyses (Table 5.4). Of the 8,273 eligible adults 
and 437 children, 2.6% adults and 1.8% children were excluded, mainly because the tumour 
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was registered from a death certificate only or detected solely at autopsy (DCO) (2.3% and 
1.1%, respectively). The proportion of tumours that were microscopically verified by 
histology or cytology, or had a specific morphology code, was 99.8% in adults and 100% in 
children. Only 1.0% of adults and 4.7% of children were lost to follow-up. 
Cancers with the highest net survival over the 14 years (2000-2013) were those of prostate, 
breast (women), and rectum in adults, and lymphoma in children. Survival was lowest for 
liver, pancreas, and lung cancer in adults, and for brain tumours in children (Table 5.5). 
During 2010-2013, one-year age-standardised net survival in adults was lowest for liver 
cancer at 37.6% (95% CI 27.8-47.3%) and highest for prostate cancer at 98.0% (94.0-
100.0%) (Figure 5.1). Survival was over 80% for five adult cancers (prostate, breast, rectum, 
cervix and colon). In children, one-year net survival for lymphoma and acute lymphoblastic 
leukaemia (ALL) was greater than 80% over the whole period (2000-2013), reaching 98.3% 
(95.2-100.0%) and 95.7% (91.2-100.0%) respectively, by 2010-2013. During 2010-2013, 
however, one-year survival for children with brain tumours was 45.2% (23.9-66.0%). 
Five-year survival in adult patients diagnosed during 2010-2013 was lowest for lung cancer 
at 13.4% (95% CI 8.8-18.0%) and highest for prostate cancer at 84.0% (74.1-94.0%) (Figure 
5.1). Prostate was the only cancer for which 5-year survival exceeded 80%. During this 
period, 5-year survival improved for lethal cancers, with four cancers showing survival below 
25% (stomach, liver, pancreas and lung) compared to five in 2000-2004 (oesophagus, 
stomach, liver, pancreas and lung) and seven in 2005-2009 (oesophagus, stomach, liver, 
pancreas, lung, brain and myeloid neoplasms). 
In children, the highest 5-year survival observed during 2010-2013 was for lymphoma 
(96.3%, 95% CI 91.4-100.0%), followed by ALL (88.4%; 80.6-96.2%). The largest 
improvement in survival in children over the 14-year period (2000-2013) was, however, for 
ALL: a 12.3% increase versus 6.3% for lymphoma. 
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For women, 1- and 5-year net survival for all cancers was between 1% and 25% higher than 
in men, with the exception of oesophagus, colon, and brain tumours, where survival was 5-
18% higher in men. The most notable differences in age-standardised five-year net survival 
between men and women were observed for myeloid neoplasms and lung cancer, which 
had a 25.1% and 13.1% difference between men (15.3%, 10.4%) and women (40.8%, 
23.5%), respectively. Survival among boys and girls was generally similar (differences less 
than 5%). 
For almost all cancers, larger differences were observed between survival at 1 and 3 years 
since diagnosis than between 3 and 5 years; reductions between 1- and 3-year survival 
ranged from 4-26% (for lymphoid neoplasms- lung) versus 1-10% (liver - colon) between 3- 
and 5-year survival. Greater reductions were seen between 1- and 3-year survival estimates 
among women than men (Figure 5.2). 
Over the 14-year period (2000-2013), 5-year survival increased for most adult cancers 
(Figure 5.3). The largest increase in age-standardised survival was for lymphoid neoplasms 
(16.1%), followed by cancers of the stomach (7.4%) and breast (6.9%). Five-year survival 
from cancers of the lung, rectum, ovary and cervix remained stable (less than 2% change), 
while survival declined for myeloid neoplasms and colon cancer in adults (13.0% and 6.3% 
respectively). 
Discussion 
This study presents a comprehensive profile of trends in population-based cancer survival 
up to five years for Kuwaiti patients diagnosed with one of 18 common cancers, by sex. It is 
the first study reporting cancer survival for males and females separately, allowing gender 
differences to be addressed. It is also the first to include shorter-term survival (1 and 3 
years), which is particularly useful for the more lethal cancers. The survival estimates 
presented here are crucial for healthcare managers and policymakers to assess the 
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effectiveness of healthcare delivery for cancer, and to plan future strategies for cancer 
control.126,127  
Our study estimated population-based survival, which is a key measure of the effectiveness 
of the health system in dealing with cancer.21 Survival estimates derived from hospital-based 
registries or clinical trials are likely to be restrictive in their selection of patients, accessibility 
to healthcare services, and availability of treatments. By contrast, population-based survival 
estimates include all patients diagnosed in a particular region. Patients are included 
irrespective of their age, stage at diagnosis, comorbidities, socio-economic status or any 
other factor. These estimates, therefore, constitute the gold standard for evaluating the 
overall effectiveness of any given health care system.20 
Obtaining high-quality, complete and reliable incidence and follow-up data on vital status for 
all cancer patients was necessary to produce robust population-based survival estimates.128 
In this study, the proportion of DCO cases among Kuwaiti patients was only 2.3% in adults 
and 1.1% in children, reducing the chance of survival overestimation.129 The total proportion 
of loss to follow-up was also low (1.2%), illustrating the efficacy of the new follow-up 
procedure performed [see paired article also published in this issue]. This new approach 
enabled follow-up data on vital status to be updated for all Kuwaiti cancer patients, using a 
mixture of both active and passive follow-up procedures, thus ensuring that all deaths were 
included in the survival analyses, regardless of the cause of death. While passive follow-up 
is a very powerful tool, in Kuwait this procedure did not allow reliable capture of information 
on the deaths of all Kuwaiti registered cancer patients. Before this study, only deaths due to 
cancer were known to the KCR, and survival estimates for Kuwait were therefore likely to 
have been overestimated. 
Our analyses show that survival for many cancers increased during 2000-2013. However, 
survival for some cancers remained static, or declined slightly, with an apparent drop in 
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survival between 2000-2004 and 2005-2009. This pattern is probably due to improvements 
in data quality over the 14-year period; the proportions of DCO and loss to follow-up were 
highest during 2000-2004 and eventually both fell to 0% for all cancers diagnosed between 
2010-2013 (except for pancreatic cancer and lymphoid neoplasms in adults, which remained 
at 1% DCO). The increases in survival observed between 2005-2009 and 2010-2013, 
despite improvements in data quality, may therefore be indicative of true advances in 
survival. 
In this study, differences in net survival by sex in Kuwait were consistent with findings from 
the United States,130 Canada,131 Europe132 and Korea,133 with women generally having an 
advantage over men. For colon cancer, however, higher survival was seen in Kuwait for 
men than women. This may be due to women having more aggressive forms of neoplasia, 
and presenting at a more advanced stage than men.134 Our study also suggested a more 
favourable prognosis for men than women with oesophageal and brain tumours, however, 
a larger cohort is required to understand better these disparities between men and women. 
For some cancers, mostly those diagnosed during 2000-2004, sparse data restricted 
interpretation of survival estimates for Kuwait. For melanoma, survival could not be 
estimated for patients diagnosed during 2000-2009, due to the small number of cases. This 
was also observed in neighbouring Gulf Arab countries (www.globocan.iarc.fr). The low 
incidence of melanoma could be attributable to the population’s skin colour, conservative 
traditional wear and limited exposure to sunlight due to high temperatures in the country. 
Pooling data over longer periods could enable more robust estimates to be produced, but 
this would hinder the examination of trends. 
The availability of updated data on follow-up for vital status allowed, for the first time, the 
inclusion of Kuwaiti data in the third cycle of the CONCORD programme, the largest and 
most up-to-date global surveillance study of cancer survival.81 The CONCORD programme 
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uses the same data quality control procedures and the same statistical methods for all 
participating countries. This means that the same time periods, cancer definitions, data 
preparation, exclusions, and analytical methods were used for all datasets. Consequently, 
this enables appropriate and robust survival comparisons to be made between results from 
this study in Kuwait and results for 70 other countries included in CONCORD-3.  
In particular, during 2010-2013, age-standardised 5-year net survival for adult patients 
diagnosed with cancer in Kuwait was generally lower than survival for patients diagnosed 
during 2010-2014 in 40 high-income non-Arab countries included in CONCORD-3.81 
Differences ranged from as little as 3-5% (compared to the average survival of the high-
income countries) for rectum, colon, lung and ovarian cancer, and from 6-19% for prostate, 
stomach, cervix and breast cancer and myeloid malignancies. By contrast, survival for 
children diagnosed with lymphoma or acute lymphoblastic leukaemia (ALL) in Kuwait was 
similar to that of other high-income countries.  
The fact that survival for adults in Kuwait is generally lower than in other high-income 
countries, particularly for stomach, prostate, breast and cervical cancer, may be partially 
explained by differences in diagnostic activity. With screening programmes available in most 
high-income countries,135-137 diagnosing asymptomatic or less aggressive and non-lethal 
tumours that do not necessarily progress to symptomatic diagnoses or death is more likely, 
thus raising survival.138 Screening can also lead to prolonged survival time and 
improvements of outcome due to early-stage diagnosis.139 Kuwait only has one breast 
cancer screening programme established in 2014,140 and is currently in the process 
of implementing a cervical cancer screening programme in 2018. It is thus necessary to 
evaluate whether the implementation of screening programmes could reduce some of the 
survival deficit between Kuwait and other high-income countries. Assessing the comorbidity 
of cancer patients in Kuwait, which tends to compromise the effectiveness and compliance 
of treatment,141 could also further help explain these differences.  
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For myeloid neoplasms, survival in Kuwait during 2010-2013 (25.6%) was considerably 
lower than in other high-income countries (e.g. 45-57% in the US, UK, Korea, Canada, 
Australia and Sweden). This may be due to differences in the subtypes of myeloid 
malignancies, which in our definition included myelodysplastic syndromes and refractory 
anaemias. These morphologies usually entail better prognosis than the more lethal subtype: 
acute myeloid leukaemia (AML).142 The lower survival in Kuwait, therefore, could be due to 
a higher proportion of patients with AML (almost 50% during this period compared to 36% 
reported in other European countries),142 reducing the pooled estimate for all myeloid 
malignancies combined. Additional comparisons of subtypes, and possibly treatment 
modalities, are thus also required to understand these differences. 
For pancreatic cancer, survival in Kuwait during 2010-2013 (23.6% CI 12.0-35.2%) was 
much higher than in other high-income countries for which reliable estimates were available 
(e.g. 6-12 % in the US, UK, Korea, Canada, Australia and Sweden). Due to the lethal nature 
of the disease, many countries had unreliable estimates, attributable to high proportions of 
DCOs. However, for Kuwait, the proportion of DCOs during this period was very low, as was 
the percentage of patients lost to follow-up (2.1% and 0% respectively; data not shown). It 
is thus unlikely that poor data quality is the cause of the high survival observed in Kuwait, 
although the relatively small number of patients (92 patients) may limit the interpretability of 
the estimates. The higher survival from pancreatic cancer may also be attributable to earlier 
stage at diagnosis or a higher proportion of neuroendocrine tumours, which are generally 
considered indolent and have a more favourable prognosis than ductal adenocarcinomas of 
the pancreas.143 Supplementary assessments on patients’ stage at diagnosis and the 
distribution of morphologies are needed in order to identify the underlying cause for this 
difference.  
Survival estimates for other Arab countries in CONCORD-3 with similar income and health 
care systems were only available for Qatar. However, most of the estimates for Qatar were 
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considered less reliable, due to the high proportion of patients censored within 5 years, 
preventing robust conclusions. Further comparisons with neighbouring countries, using 
complete and high-quality data, are therefore necessary to determine whether differences 
between regions that share similar culture, tradition, climate, income and healthcare 
systems do in fact reflect true inequalities in cancer care. 
Conclusion 
During the 14-year period up to 2013, cancer survival improved for most Kuwaiti adults and 
children. Survival for some cancers remained static or even declined, and this requires 
continuous surveillance and monitoring. Women generally have a more favourable 
prognosis than men.  
These results should prompt ministerial health planners and politicians in Kuwait to allow 
robust estimates to be produced through continuous surveillance of population-based 
cancer survival, and the systematic provision of cancer data and follow-up information on 
vital status for all cancer patients. The data presented here should assist policymakers and 
practitioners investing in the Kuwaiti healthcare system to achieve optimal outcomes by 
promoting early diagnosis and screening programmes and detecting and treating cancer 
more efficiently. 
Further research is required to help dissect the underlying causes for the differences in 
survival between Kuwait and other countries with comparable income and health systems, 
in order to investigate whether the differences are attributable to late diagnosis, treatment, 











Table 5.2 Definition of adult haematological malignancies 
 
 
No. Description Lymphoid neoplasms Myeloid neoplasms
1       Lymphoma NOS 9590
2       NH Lymphoma NOS 9591, 9597
3       Composite HL and NHL 9596
4       HL nodular lymphocyte 
predominance
9659
5       Classical HL 9650, 9661, 9662, 9651, 9663, 
9664, 9665, 9667, 9652, 9653, 
9654, 9655
6       CLL/SLL 9670, 9823
7       Immunoproliferative diseases 9760, 9671, 9761, 9762
8       Mantle cell/centrocytic 9673
9       Follicular B lymphoma 9690, 9691, 9695, 9698
10     Diffuse B lymphoma 9675, 9678, 9679, 9680, 9684, 
9688, 9712, 9735, 9737, 9738
11     Burkitt’s leukaemia/lymphoma 9687, 9826
12     Marginal zone lymphoma 9689, 9699, 9764
13     T lymphoma cutaneous 9700, 9701, 9709, 9718, 9708, 
9726
14     Other T cell lymphoma 9702, 9705, 9714, 9716, 9717, 
9725, 9948, 9719, 9827, 9831, 
9834
15     Lymphoblastic lymphoma/acute 
(precursor cell) lymphoblastic 
leukaemia
9727, 9728, 9729, 9811, 9812, 
9813, 9814, 9815, 9816, 9817, 
9818, 9835, 9836, 9837
16     Plasma cell neoplasms 9731,9732, 9733, 9734
17     Mature B cell leukaemia 9833
18     Mature B-cell leukaemia, hairy 9940
19     Lymphatic leukaemia NOS 9820, 9832
20     Leukaemia NOS 9800, 9801, 9805, 9806, 9807, 9808, 
9809
21     Myeloid leukaemia NOS 9860, 9898
22     Acute myeloid leukaemia 9840, 9861, 9865, 9866, 9867, 9869, 
9870, 9871, 9872, 9873, 9874, 9891, 
9895, 9896, 9897, 9910, 9911, 9920, 
9930, 9931, 9984, 9987
23     Myeloproliferative neoplasms* 9740, 9741, 9742, 9863, 9875, 9950, 
9960, 9961, 9962, 9963, 9964
24     Myelodysplastic syndrome 9980, 9982, 9983, 9985, 9986, 9989, 
9991, 9992
25     Myelodysplastic/myeloprolifera
tive neoplasms**
9945, 9876, 9946, 9975
NOS: Not otherwise specified, * this group includes chronic myeloid leukaemias (several morphology 
codes), ** Note: this group includes chronic myelomonocytic leukaemia (M-9945) and Juvenile 
Myelomonocytic leukaemia (M-9946)











Table 5.4 Data quality indicators for patients diagnosed during 2000-2013, for adults and children by cancer site 
 
Table 4
   Total








M F M F M F
Adult cancers
Oesophagus 97 0.0 0.0 97 7.2 0.0 12 15 12 12 26 13 90 100.0 0.0 2.2
Stomach 233 0.0 6.4 218 5.0 0.0 35 24 48 31 36 33 207 100.0 0.0 1.0
Colon 938 0.1 0.3 934 2.8 0.0 106 131 165 160 172 174 908 100.0 0.0 2.2
Rectum 335 0.0 0.3 334 1.2 0.0 37 48 64 66 60 55 330 100.0 0.0 0.9
Liver 303 0.0 0.3 302 13.2 0.3 48 20 75 31 62 25 261 100.0 0.4 1.1
Pancreas 265 0.0 0.4 264 8.3 0.8 31 26 54 37 46 46 240 100.0 0.4 0.8
Lung 586 0.2 0.2 584 4.3 0.0 131 49 142 49 135 53 559 100.0 0.2 1.3
Melanoma 21 0.0 14.3 18 0.0 0.0 2 3 2 5 4 2 18 100.0 0.0 0.0
Breast 2,698 3.6 0.2     2,595 0.5 0.6 0 628 0 953 0 987 2,568 100.0 0.1 0.4
Cervix 183 9.8 0.0 165 1.2 0.0 0 62 0 59 0 42 163 100.0 0.0 0.6
Ovary 279 0.0 17.6 230 2.6 1.3 0 62 0 92 0 67 221 99.5 0.9 0.5
Prostate 521 0.6 0.0 518 1.7 0.0 116 0 169 0 224 0 509 100.0 0.0 0.8
Brain 259 0.0 0.0 259 8.9 2.3 42 25 50 34 42 37 230 96.5 3.9 0.9
Myeloid neoplasms 350 0.0 0.6 348 0.6 0.0 44 40 77 59 68 58 346 98.8 2.6 0.9
Lymphoid neoplasms 1,409 0.0 0.1 1,407 0.1 0.0 208 167 330 207 271 222 1,405 99.6 0.8 1.6
Total         8,477 1.4 1.0     8,273 2.3 0.3   812   1,300  1,188  1,795  1,146   1,814  8,055 99.8 0.4 1.0
Childhood cancers
Brain 57 0.0 0.0 57 8.8 5.3 13 5 16 6 5 4 49 100.0 0.0 2.0
ALL 251 0.0 0.0 251 0.0 0.0 54 29 55 43 40 30 251 100.0 0.0 5.2
Lymphoma 146 0.0 11.6 129 0.0 0.0 35 13 29 16 23 13 129 100.0 1.6 4.7
Total 454 0.0 3.7 437 1.1 0.7 102 47 100 65 68 47 429 100.0 0.5 4.7
¶ In s i tu mal ignant disease (ICD-O-3 behaviour code 2). Other: records  with incomplete data; or tumours  that are benign (behaviour code 0), of uncerta in behaviour 
(1), metastatic from another organ (6), or unknown i f primary or metastatic (9); or patients  fa l l ing outs ide the age range 0–14 years  (chi ldren) or 15–99 years  (adults ); 
or other conditions . ||DCO=tumours  regis tered from a  death certi fi  cate only or detected solely at autopsy. Other: vi ta l  s tatus  or sex unknown; or inval id sequence of 
dates ; or incons is tency of sex-s i te, s i te-morphology,      age-s i te, age-morphology, or age-s i te-morphology. †† MV=microscopica l ly veri fied. Non-speci fic morphology 
(sol id tumours  only): ICD-O-3 morphology code in the range 8000–8005.
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Table 5.5 Age-standardised net survival (NS, %) at one, three and five years, Kuwaiti adults (15-99 years) and children (0-14 
years) diagnosed during 2000-2013, followed to 31 December 2014
 
Males Females Both sexes
NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI
Adults
Oesophagus 1 year 56.0 27.9 - 84.1 30.6 5.0 - 56.1 53.1 31.9 - 74.4 34.4 11.6 - 57.3 26.2 3.0 - 49.4 45.3 20.6 - 70.0 44.2 § 25.3 - 63.1 28.4 10.3 - 46.5 50.3 33.6 - 66.9
3 years 21.8 0.0 - 44.7 0.1 0.0 - 0.3 32.0 11.7 - 52.3 14.4 0.0 - 31.0 17.7 0.0 - 37.3 15.2 0.0 - 32.2 17.6 § 2.9 - 32.4 9.5 0.0 - 20.6 25.0 10.3 - 39.8
5 years 21.8 0.0 - 44.7 .. 32.3 11.8 - 52.8 14.4 0.0 - 31.0 17.7 0.0 - 37.3 15.7 0.0 - 33.3 17.6 § 2.9 - 32.4 9.5 0.0 - 20.6 25.4 10.5 - 40.4
Stomach 1 year 53.6 36.5 - 70.8 57.2 43.1 - 71.2 49.0 35.0 - 63.1 46.6 27.0 - 66.2 45.5 28.2 - 62.7 51.4 41.4 - 61.3 45.8 32.5 - 59.2 47.4 37.7 - 57.2 50.5 39.2 - 61.8
3 years 29.6 13.7 - 45.4 21.3 9.8 - 32.9 23.7 11.1 - 36.4 17.1 2.7 - 31.6 19.8 6.3 - 33.4 15.4 7.2 - 23.5 20.3 11.0 - 29.5 16.1 10.1 - 22.1 27.9 16.0 - 39.8
5 years 19.9 5.2 - 34.6 13.1 3.7 - 22.5 14.5 2.9 - 26.2 17.1 2.7 - 31.6 19.8 6.3 - 33.4 15.5 7.3 - 23.7 15.0 7.1 - 22.9 13.4 7.1 - 19.7 22.4 12.6 - 32.3
Colon 1 year 86.1 78.0 - 94.2 73.2 64.0 - 82.5 86.4 79.5 - 93.3 85.4 80.6- 90.2 79.0 70.4 - 87.6 77.0 68.0 - 86.1 85.8 79.0 - 92.5 76.1 69.6 - 82.6 82.6 76.7 - 88.4
3 years 73.1 61.1 - 85.0 59.3 48.7 - 69.8 76.6 66.0 - 87.1 70.1 62.9- 77.2 60.2 50.5 - 69.9 60.3 50.2 - 70.4 72.7 63.0 - 82.3 59.5 52.1 - 66.9 68.9 61.0 - 76.7
5 years 62.6 48.6 - 76.5 48.0 37.9 - 58.0 58.8 45.0 - 72.6 59.6 51.0- 68.3 51.8 41.7 - 62.0 54.1 42.8 - 65.3 64.8 53.1 - 76.5 50.2 42.7 - 57.7 58.5 49.4 - 67.7
Rectum 1 year 90.4 80.0 - 100.0 93.4 88.3 - 98.4 86.0 77.1 - 95.0 86.4 79.1- 93.7 90.6 83.2 - 98.0 93.5 84.9 - 100.0 87.0 81.6 - 92.4 92.3 86.5 - 98.2 87.9 80.5 - 95.3
3 years 69.1 52.7 - 85.6 64.2 55.6 - 72.8 66.0 54.5 - 77.4 74.2 63.6- 84.8 78.6 67.7 - 89.5 69.1 55.2 - 82.9 70.6 62.5 - 78.7 67.1 55.9 - 78.3 67.0 57.6 - 76.4
5 years 59.3 41.6 - 77.0 54.0 44.9 - 63.1 55.1 42.4 - 67.8 60.2 47.8- 72.7 66.1 53.5 - 78.8 56.7 41.4 - 72.0 59.3 48.1 - 70.4 53.3 42.4 - 64.2 58.2 48.5 - 67.9
Liver 1 year 37.2 23.4 - 51.1 38.3 27.1 - 49.5 31.1 19.6 - 42.6 27.2 8.1 - 46.2 32.8 16.6 - 48.9 52.4 34.7 - 70.1 34.3 § 22.8 - 45.8 36.8 27.4 - 46.1 37.6 27.8 - 47.3
3 years 13.6 3.8 - 23.5 15.9 7.4 - 24.4 9.8 2.8 - 16.9 16.3 0.9 - 31.8 17.5 4.4 - 30.6 27.8 12.3 - 43.3 14.6 § 5.9 - 23.2 16.5 9.2 - 23.8 19.4 11.5 - 27.4
5 years 8.6 0.5 - 16.7 10.9 3.6 - 18.3 7.9 1.6 - 14.2 16.3 0.9 - 31.8 15.2 2.6 - 27.7 26.7 10.2 - 43.2 11.4 § 3.5 - 19.2 12.4 5.8 - 19.1 18.6 9.8 - 27.3
Pancreas 1 year 24.0 9.2 - 38.9 20.7 10.0 - 31.3 33.7 19.9 - 47.4 32.3 14.5 - 50.0 38.3 22.8 - 53.7 48.9 34.2 - 63.6 27.8 § 16.0 - 39.5 24.3 17.2 - 31.4 40.9 30.1 - 51.8
3 years 10.1 0.5 - 19.8 3.8 0.0 - 8.4 13.9 3.3 - 24.4 16.2 2.6 - 29.9 22.5 9.3 - 35.8 19.0 7.0 - 30.9 12.9 § 4.3 - 21.6 10.6 5.2 - 16.0 22.3 12.5 - 32.2
5 years 10.1 0.5 - 19.8 1.9 0.0 - 5.0 10.9 1.1 - 20.7 12.3 0.3 - 24.3 17.3 5.1 - 29.6 16.4 4.8 - 28.0 11.2 § 3.1 - 19.3 7.0 3.0 - 11.0 23.6 12.0 - 35.2
Lung 1 year 37.7 29.6 - 45.9 43.9 35.5 - 52.4 41.0 32.8 - 49.2 33.2 20.1 - 46.3 49.5 35.4 - 63.6 58.7 49.5 - 68.0 35.9 28.4 - 43.4 46.4 39.2 - 53.7 46.3 39.4 - 53.1
3 years 14.2 9.6 - 18.8 26.0 18.0 - 34.0 16.6 10.4 - 22.7 20.7 9.1 - 32.2 22.1 10.1 - 34.0 23.2 13.7 - 32.8 15.1 10.3 - 19.9 25.1 18.5 - 31.8 19.9 14.4 - 25.5
5 years 14.5 7.8 - 21.2 15.7 9.9 - 21.6 10.4 5.8 - 15.0 11.6 2.5 - 20.6 17.5 6.5 - 28.5 23.5 13.8 - 33.2 13.3 8.9 - 17.7 16.3 11.1 - 21.5 13.4 8.8 - 18.0
Melanoma 1 year .. .. .. .. .. .. .. .. 67.5 32.8 - 100.0
of the skin 3 years .. .. .. .. .. .. .. .. 71.0 34.4 - 100.0
5 years .. .. .. .. .. .. .. .. 49.0 0.0 - 98.4
Breast 1 year .. .. .. 95.1 91.5- 98.7 92.2 88.4 - 95.9 93.3 89.9 - 96.7 .. .. ..
(women) 3 years .. .. .. 82.5 74.4- 90.6 76.7 70.7 - 82.7 83.2 77.0 - 89.4 .. .. ..
5 years .. .. .. 68.3 58.0- 78.7 71.0 63.8 - 78.2 75.2 66.4 - 83.9 .. .. ..
§ Survival estimate considered less reliable (i.e. proportion of patients lost to follow-up or registered only from a death certificate or at autopsy is greater than 15%); Italics denote survival estimates that are not age-
standardised; ALL, Acute lymphoblastic leukaemia
2000-2004 2005-2009 2010-20132000-2004 2005-2009 2010-2013 2000-2004 2005-2009 2010-2013
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Table 5.5 (continued) Age-standardised net survival (NS, %) at one, three and five years, Kuwaiti adults (15-99 years) and 
children (0-14 years) diagnosed during 2000-2013, followed to 31 December 2014 
 
Males Females Both sexes
NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI
Adults
Cervix 1 year .. .. .. 79.0 73.7 - 84.3 88.7 80.4 - 97.0 85.7 77.3 - 94.2 .. .. ..
3 years .. .. .. 57.9 49.1 - 66.6 79.9 69.1 - 90.7 60.5 48.3 - 72.7 .. .. ..
5 years .. .. .. 54.8 45.2 - 64.3 73.8 61.7 - 86.0 56.6 44.2 - 69.0 .. .. ..
Ovary 1 year .. .. .. 73.4 62.2 - 84.5 72.6 65.5 - 79.7 75.6 68.5 - 82.6 .. .. ..
3 years .. .. .. 60.5 47.8 - 73.2 43.4 34.4 - 52.4 43.0 34.6 - 51.3 .. .. ..
5 years .. .. .. 38.9 26.3 - 51.5 35.4 25.2 - 45.6 35.1 25.6 - 44.7 .. .. ..
Prostate 1 year 88.8 82.0 - 95.5 91.0 86.6 - 95.4 98.0 94.3 - 100.0 .. .. .. .. .. ..
3 years 79.9 70.3 - 89.6 79.1 72.6 - 85.7 93.4 87.3 - 99.5 .. .. .. .. .. ..
5 years 78.8 66.7 - 90.9 71.9 63.7 - 80.0 84.0 74.1 - 94.0 .. .. .. .. .. ..
Brain 1 year 50.2 35.2 - 65.3 60.7 47.1 - 74.3 81.3 69.3 - 93.2 59.7 40.7 - 78.8 67.9 52.3 - 83.5 70.3 55.5 - 85.1 53.7 § 41.7 - 65.6 59.1 50.6 - 67.6 68.0 60.9 - 75.2
3 years 30.4 16.5 - 44.3 26.7 14.5 - 38.8 50.4 35.0 - 65.8 34.2 15.8 - 52.7 44.6 28.1 - 61.2 38.6 22.6 - 54.5 31.7 § 20.4 - 43.0 29.4 21.4 - 37.5 37.3 28.5 - 46.1
5 years 28.0 14.4 - 41.6 20.2 9.1 - 31.3 42.3 25.8 - 58.8 34.2 15.8 - 52.7 41.9 25.4 - 58.3 34.6 18.5 - 50.8 30.3 § 19.1 - 41.5 24.9 17.3 - 32.6 31.8 23.2 - 40.4
Myeloid 1 year 61.9 47.5 - 76.4 33.1 23.4 - 42.8 49.5 35.6 - 63.4 80.1 67.8 - 92.5 71.5 60.0 - 83.0 58.5 49.6 - 67.4 55.0 46.8 - 63.3 42.2 31.2 - 53.3 50.2 40.1 - 60.3
neoplasms 3 years 53.1 38.0 - 68.2 23.0 14.5 - 31.5 17.9 9.4 - 26.5 67.6 53.0 - 82.3 59.9 47.3 - 72.4 39.2 30.2 - 48.3 44.3 35.3 - 53.3 27.9 19.1 - 36.8 28.6 20.2 - 37.0
5 years 48.5 33.1 - 64.0 17.0 11.0 - 23.0 15.3 7.9 - 22.8 63.1 47.8 - 78.4 58.7 45.9 - 71.5 40.5 31.1 - 49.9 38.6 27.1 - 50.0 24.0 15.9 - 32.0 25.6 17.7 - 33.6
Lymphoid 1 year 69.7 60.0 - 79.5 77.7 70.9 - 84.5 77.3 68.5 - 86.1 71.1 60.7 - 81.6 72.1 62.0 - 82.2 78.9 70.1 - 87.8 70.8 63.4 - 78.1 76.7 71.1 - 82.4 78.5 72.2 - 84.8
neoplasms 3 years 52.4 41.5 - 63.4 67.0 58.5 - 75.5 74.6 64.5 - 84.7 61.4 49.4 - 73.5 67.6 55.7 - 79.6 72.0 61.5 - 82.5 56.7 48.4 - 65.0 68.4 61.5 - 75.4 74.1 66.7 - 81.5
5 years 45.3 34.5 - 56.2 59.9 50.8 - 69.0 65.5 54.4 - 76.6 54.1 41.9 - 66.3 65.8 53.7 - 77.8 73.8 62.0 - 85.5 52.1 42.9 - 61.2 63.2 55.8 - 70.7 68.2 59.5 - 76.9
Children
Brain 1 year 75.0 51.7 - 98.4 81.3 62.8 - 99.7 48.0 12.5 - 83.5 .. .. 50.0 9.2 - 90.8 82.4 64.8 - 99.9 77.3 60.2 - 94.4 45.2 23.9 - 66.6
3 years 41.7 15.7 - 67.7 62.6 39.8 - 85.3 24.0 0.0 - 50.5 .. .. 25.0 0.0 - 56.9 53.0 30.2 - 75.8 63.7 44.1 - 83.2 20.7 3.3 - 38.0
5 years 33.4 8.8 - 58.0 56.4 33.0 - 79.7 20.6 0.0 - 44.0 .. .. 25.0 0.0 - 56.9 47.1 24.4 - 69.8 59.2 39.2 - 79.1 18.4 2.6 - 34.3
ALL children 1 year 88.42 81.7 - 95.2 80.0 68.5 - 91.5 95.1 88.5 - 100.0 100.0 87.7 - 100.0 90.5 85.0 - 95.9 96.9 92.9 - 100.0 89.8 § 81.7 - 97.9 85.7 77.9 - 93.4 95.7 91.2 - 100.0
3 years 82.6 74.5 - 90.7 73.4 60.9 - 85.9 90.1 80.6 - 99.7 95.7 87.6 - 100.0 84.3 77.8 - 90.8 94.4 89.5 - 99.3 84.5 § 75.1 - 93.8 78.4 69.5 - 87.2 91.0 84.1 - 98.0
5 years 71.26 61.6 - 80.9 70.1 57.2 - 82.9 88.9 79.1 - 98.7 90.7 78.6 - 100.0 81.2 73.8 - 88.5 91.7 84.7 - 98.7 76.1 § 65.7 - 86.5 74.9 65.6 - 84.1 88.4 80.6 - 96.2
Lymphoma 1 year 98.3 95.0 - 100.0 96.3 91.6 - 100.0 100.0 87.2 - 100.0 92.3 78.4 - 100.0 93.8 82.3 - 100.0 96.7 90.8 - 100.0 97.5 94.3 - 100.0 95.6 90.8 - 100.0 98.3 95.2 - 100.0
3 years 94.1 88.1 - 100.0 96.3 91.6 - 100.0 100.0 80.5 - 100.0 92.3 78.4 - 100.0 87.5 71.8 - 100.0 96.7 90.8 - 100.0 94.4 88.9 - 99.9 93.1 87.4 - 98.8 98.4 95.3 - 100.0
5 years 92.1 85.0 - 99.2 92.7 86.1 - 99.3 96.7 90.8 - 100.0 92.3 78.4 - 100.0 87.5 71.8 - 100.0 96.7 90.8 - 100.0 93.0 86.2 - 99.8 90.7 83.2 - 98.2 96.3 91.4 - 100.0
2000-2004 2005-2009 2010-2013 2000-2004
§ Survival estimate considered less reliable (i.e. proportion of patients lost to follow-up or registered only from a death certificate or at autopsy is greater than 15% ); Italics denote survival estimates that are not age-standardised; 
ALL, Acute lymphoblastic leukaemia




Figure 5.1 Age-standardised 1- and 5-year net survival (%) in adults (15-99 years) and children (0-14 years); Kuwait, 
patients diagnosed during 2000-2013 
 ALL: Acute lymphoblastic leukaemia; § Survival estimate considered less reliable (i.e. proportion of lost to follow-up within five years ≥ 15%); * Survival estimates not age-standardised 






































































Figure 5.2 Age-standardised 1- and 5-year net survival (%) in adults (15-99 years) and children (0-14 years); Male and 
female patients diagnosed during 2010-2013 
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Figure 5.3 Trends in age-standardised five-year net survival (%) in Kuwaiti adults (15-99 years) and children (0-14 














































































































































































































In the previous chapter, net survival up to 5 years was estimated for Kuwaiti patients 
diagnosed with one of 18 common cancers over a 14-year period (2000-2013). Survival has 
improved for most cancers, but differences were observed between cancer survival in 
Kuwait and in other high-income countries included in CONCORD-3.  
Stage at diagnosis is a key predictor of patients’ outcome. The distribution of stage at 
diagnosis can provide a useful evaluation of diagnostic activity, the level of knowledge of 
cancer symptoms in the general population, and the thoroughness of the staging procedures 
in a given country or region. Examination of population-based survival trends by stage at 
diagnosis also provides a more thorough understanding of the cancer care system and its 
ability to provide timely and optimal stage-specific treatment. Stage-specific survival may 
also help explain differences in survival between populations and regions. 
The aim of this chapter is to extend the evaluation of survival in Kuwait through examining 
the distribution of Surveillance Epidemiology and End Results (SEER) Summary Stage at 
diagnosis for 12 cancers in Kuwait during 2000-2013, and assessing stage-specific net 
survival at 1 and 5 years. Comparisons of stage-specific survival between Kuwait and the 
United States are performed for colon, lung and breast cancer, using the same staging 
system, calendar period, cancer definitions, data quality control procedures and analytical 
methods.  
The results of this chapter revealed that early diagnosis was not very frequent in Kuwait 
throughout the period 2000-2013, highlighting the need for urgent investment in early 
detection, as well as increasing public awareness of cancer symptoms and its risk factors. 
The completeness of data on the stage of diagnosis for cancer patients in Kuwait also 
appeared to decline over the 14-year period in Kuwait. This emphasises the need for further 
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investment in the Kuwait Cancer Registry, and improved access to patients’ medical data to 
aid the ascertainment of data on stage at diagnosis. 
Stage-specific survival estimates highlighted cancers for which earlier diagnosis could 
achieve the greatest benefit. Differences in stage-specific survival between Kuwait and the 
US also revealed that late diagnosis in Kuwait could be a major contributing factor to the 
lower survival for all patients combined. This could also partially explain the difference in 
survival between Kuwait and the US, and possibly other high-income countries as well.   
In this chapter, I have achieved the third objective of my thesis: to assess the distribution of 
stage at diagnosis for 12 cancers in Kuwait, and to estimate stage-specific net survival at 1 
and 5 years, to improve understanding of any disparities in cancer survival between Kuwait 
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Stage at diagnosis, the anatomic extent of a disease, is a major determinant of patients’ 
outcomes.144 It is crucial in predicting patients’ prognosis and to inform treatment decisions, 
as well as to assess the effect of public health interventions such as screening programmes 
and educational or awareness campaigns, which aim to improve early-stage diagnosis. 
Stage information is also valuable to help plan the provision of cancer-related resources and 
services, to monitor compliance to treatment guidelines, and to offer more detailed analyses 
of cancer outcomes.145 
Evaluation of the distribution of stage at diagnosis helps to assess the intensity of diagnostic 
activity in a given country or region. Examination of population-based survival trends by 
stage at diagnosis helps to determine the effectiveness of the health system in offering 
stage-specific optimal treatment to all patients. In Kuwait, net survival was lower than in 
other high-income countries.146 Differences in the distribution of stage at diagnosis are likely 
to be a key determinant of these discrepancies. The distribution of stage at diagnosis for 
each cancer can also reflect the level of symptom awareness, as well as the thoroughness 
of the staging procedures within a region or country.147 
Population-based cancer survival by stage has never been assessed in Kuwait. In order to 
provide a better understanding of cancer survival in the country, our study aims to assess 
the distribution of stage at diagnosis in Kuwait for 12 cancers for which data are available, 
and to estimate stage-specific net survival at 1 and 5 years since diagnosis. Differences in 




Material and methods 
We obtained data from the Kuwait Cancer Registry for all adult Kuwaiti patients (aged 15-
99 years) diagnosed during 2000-2013 with one of 18 malignancies.81,146 Data on stage were 
available for 12 cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, 
melanoma, breast (women), cervix, ovary and prostate. All tumours were defined by 
anatomical site (topography), and coded to the International Classification of Diseases for 
Oncology (third edition, ICD-O-3)115 and its first revision.116 
Data were assessed for quality and completeness according to the protocol and 
standardised quality-control procedures from the CONCORD programme for global 
surveillance of cancer survival.148 Records considered ineligible for survival analyses were 
excluded. Full details of exclusions and data quality indicators have been published.146 
Follow-up data were available until 31 December 2015. Information on follow-up was 
obtained using a new method149 combining active and passive follow-up procedures, which 
has been shown to be highly effective in ascertaining each patient’s vital status. Complete 
dates of death of deceased cancer patients were obtained from the Central Records 
Department of Births and Deaths, at Kuwait’s Ministry of Health. When the vital status could 
not be ascertained, the patients were considered lost to follow-up, and were censored from 
survival analyses at the date most recently known to be alive from medical records. 
We present the distribution of stage at diagnosis for the 12 malignancies based on the 
Surveillance Epidemiology and End Results (SEER) Summary Stage 2000,150 which 
categorises the extent of the disease as localised, regional (with lymph node involvement, 
or direct extension, or both) or distant metastasis.  
Patients were grouped into 3 consecutive calendar periods (2000-2004, 2005-2009 and 
2010-2013). We estimated stage-specific net survival only for cancers with at least 10 
patients in each stage category and calendar period. Due to low numbers for most cancers, 
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we present unstandardised 1- and 5-year stage-specific survival estimates for all ages 
combined. 
Standardisation is crucial when comparing populations or regions that differ with respect to 
age. Due to Kuwait’s relatively small population and the rarer nature of some cancers, 
however, age-standardisation was only possible for three cancers: colon, lung and breast. 
To make comparisons between Kuwait and the US, stage-specific survival estimates were 
obtained from the CONCORD-2 supplementary studies on US data for colon,151 lung152 and 
breast cancer.153 To be able to compare results in Kuwait with the US, survival was 
estimated for the calendar period 2004-2009. For these analyses, we present age-
standardised stage-specific 5-year net survival, where possible. 
Net survival is the probability for cancer patients to survive their cancer up to a given time 
following diagnosis (e.g., 1 or 5 years), after correcting for competing causes of death 
(background mortality). To control for background mortality, we used life tables of all-cause 
mortality in the general population. We used life tables by single year of age (“complete” life 
tables), sex, calendar year of death, and nationality (Kuwaiti, non-Kuwaiti).148 
We used the Pohar-Perme estimator86 to estimate net survival, implemented with the 
programme stns122 in Stata version 14.154 This estimator accounts for the fact that the hazard 
of death due to causes other than cancer (competing causes) is higher among older patients.  
For patients diagnosed during 2000-2003 and 2004-2009, the cohort approach was used to 
estimate survival. The cohort approach is considered the gold standard,85 and can be used 
only when all patients in the cohort have had the opportunity to be followed up for the full 
duration of the follow-up required, in this case, five years. For patients diagnosed during 
2010-2013, the complete approach was used because five years of follow-up data were not 
available for all patients by December 2015. This approach enables survival estimates to be 
produced for recently diagnosed patients.89 
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Net survival estimates were age-standardised where possible, using the International 
Cancer Survival Standard (ICSS) weights,92 in which age at diagnosis is categorised into 5 
groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. The 95% confidence intervals (CI) for 
all unstandardised and age-standardised estimates were derived assuming a normal 
distribution, truncated to the range 0-100. Confidence intervals were constructed using 
standard errors calculated using the Greenwood method.125 When no deaths or censorings 
occurred within 5 years, or if all patients died (survival probability 1 or 0), a binomial 
approximation was obtained for the upper and lower bound of the CI. 
Results 
Colon (46.6%), rectal (39.7%), breast (49.4%) and cervical cancer (36.2%) were most 
commonly diagnosed at regional stage, while liver (29.9%), pancreas (48.3%) and lung 
(41.2%) were mostly diagnosed at distant stage (Table 6.1). For oesophagus (~23%), 
stomach (~32%), melanoma (~22%) and ovary (~32%), the proportion of stage at diagnosis 
was similar for both regional and distant stage. The proportion of men diagnosed with 
prostate cancer at localised stage (25.7%) was similar to the proportion of men diagnosed 
at distant stage (24.0%). 
Overall, stage data were available for 74.1% of patients diagnosed during 2000-2013. This 
proportion decreased from 88.9% in 2000-2004 to 59.4% in 2010-2013. Over this 14-year 
period, the highest proportion of unknown stage was for liver (52.1%) and oesophageal 
cancer (42.2%); the lowest was for colon (19.1%) and breast cancer (21.1%). 
Between 2000-2004 and 2005-2009, when the availability of data on stage was reasonably 
high, a common trend was observed in the stage distribution for most cancers: the proportion 
of patients diagnosed at localised and regional stage decreased, while that of distant and 
unknown stage increased. The exceptions were colon and liver cancer, where the proportion 
of patients diagnosed at localised stage remained similar, and cancers of the breast and 
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prostate, where the proportion diagnosed at a localised stage increased slightly (18.7% to 
22.4%, and 23.3 to 25.4%, respectively).    
Stage-specific survival 
In general, survival for all cancers was lower for patients diagnosed at more advanced stage 
(Table 6.2). For patients diagnosed during 2010-2013, for whom unknown stage at diagnosis 
was the highest, survival for patients with unknown stage was either similar or higher than 
the survival of all stages combined, for almost all cancers. This trend was also observed for 
patients diagnosed with unknown stage during 2000-2004 and 2005-2009. 
During 2005-2009, one-year survival for colon, rectal, breast and ovarian cancer was 
generally similar for patients diagnosed at localised or regional stage (Figure 6.1). One- and 
five-year survival for colon, rectal, breast, cervical and prostate cancer, was high (almost 
90% or higher) and relatively similar, for patients diagnosed at localised stage. Five-year 
survival for all cancers was relatively low, ranging from 43.5% for prostate to 0% for stomach, 
for patients diagnosed at distant stage. 
During the same period, the greatest difference in five-year survival between regional and 
distant stage at diagnosis, was observed for colon, rectum and breast (>50%), followed by 
prostate, stomach and ovary (about 30%). For some of the more lethal cancers, the 
difference in one-year survival between regional and distant stage was substantially smaller 
(around 25%), e.g., for stomach (70.4% vs. 44.7%) and pancreatic cancer (47.1% vs. 
18.6%). 
Comparisons between Kuwait and the United States 
During 2004-2009, the proportion of patients diagnosed at localised stage was substantially 
lower in Kuwait than in the US for colon (10.7% vs. 37.8%) and breast (21.9% vs. 59.1%), 
while the proportions of regional, distant and unknown stages were higher, with differences 
ranging from 5% to 21% (Figure 6.2). For lung cancer, the proportion of localised stage was 
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much lower in Kuwait than in the US (3.5% vs.17.7%), however the proportion was similar 
in the two countries for regional (22.5% vs. 23.4%) and distant stage (47.6% vs. 50.0%).  
Age-standardised five-year net survival in Kuwait for all stages combined for colon (50.6%), 
lung (15.3%) and breast (70.8%) was lower than in the US (64.6%, 19.0% and 88.6%, 
respectively) (Table 6.3).  
For colon cancer, stage-specific five-year net survival was similar in Kuwait and the US for 
both regional disease (73.0% vs. 70.2%, and distant stage (13.7% vs. 13.8%).  
For lung cancer, the only age-standardised stage-specific survival estimate available for 
Kuwait was for distant stage. Survival for patients diagnosed at distant stage in Kuwait was 
somewhat higher than in the US (8.0% vs. 4.8%). For breast cancer, stage-specific survival 
was generally similar in Kuwait and the US: slightly lower for localised stage (94.4% vs. 
98.3%) and slightly higher for distant stage (28.4% vs. 24.5%). For regional stage, stage-
specific survival in Kuwait was lower than in the US (75.7% vs. 82.3%).  
Discussion 
This is the first population-based study to date in Kuwait to assess the distribution of stage 
at diagnosis and stage-specific survival, over a 14-year period, for up to 12 malignancies. 
To examine the distribution of stage at diagnosis is essential to interpret the variations in 
survival over time and helps identify cancers for which earlier diagnosis can achieve the 
greatest benefit. Differences in population-based survival between different populations or 
regions may also be partly explained by differences in stage of disease at diagnosis.155,156 
This study produced stage-specific net survival estimates up to 5 years for colon, lung and 
breast cancer, taking into account the differences in the age profile of cancer patients and 
the risk of death from other causes, thus enabling robust comparisons of stage-specific 
survival over time. 
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Age-standardisation is essential to compare survival over time, or between different regions, 
since net survival can vary considerably by age, and the age structure of cancer patients 
differs between countries and over time. However, due to the small number of patients 
available for analysis in Kuwait, age-standardisation by stage was not possible for many 
cancers. Comparisons of stage-specific survival over time in Kuwait were therefore 
performed using unstandardised estimates.  
During 2000-2013, stage was known for 74% of the patients. The proportion of patients with 
known stage decreased over the 14-year period, reaching its lowest (59%) during 2010-
2013. The mean age, as well as the age distribution, were also generally similar for the 
patients with known and unknown stage at diagnosis during 2010-2013, with exception to 
pancreatic cancer, where the proportion of older patients (> 85 years) was greater among 
patients with unknown stage. The survival for patients with known stage, for most cancers, 
was also generally similar to that for patients with unknown stage. The unavailability of 
information on stage in this case is therefore less likely due to physicians’ staging practices, 
or to patients not being medically fit for staging and treatment. A plausible explanation could 
be that more patients are receiving their first treatment abroad, and therefore are not staged 
in Kuwait. Receiving treatment abroad is a service provided by the government, covering 
full treatment costs. With the Ministry of Health’s increased budget for overseas treatment 
in 2009, more patients have been utilising this option.157 The increased proportion of 
unknown stage for patients diagnosed during 2010-2013, could thus be due to more patients 
receiving treatments abroad.  
During 2005-2009, 1- and 5-year stage-specific survival for patients diagnosed at localised 
stage was about 90% or higher for colon, rectal, breast, cervical and prostate cancer. In 
Kuwait, these cancers are most commonly diagnosed at regional stage, and the proportion 
of patients diagnosed at localised stage is low, ranging from 25.4% for prostate to 10.5% for 
colon cancer. Furthermore, the largest difference in survival was observed between patients 
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diagnosed at regional and distant stage. This difference in five-year net survival was most 
evident (greater than 50%) for cancers of the colon, rectum and breast, followed by those of 
prostate, stomach and ovary, where this difference was about 30%. This further highlights 
the cancers for which early diagnosis is important, and where greater efforts are essential 
to ensure that more patients are diagnosed at an earlier stage, particularly for cancers for 
which early detection tests and procedures are available.137 
For colon, lung and breast, we compared survival in Kuwait to that in the US, where survival 
is among the highest worldwide.81 We used the calendar period, cancer definitions, data 
quality control procedures and analytical methods used for the CONCORD-2 supplementary 
analyses of stage-specific survival for the US,95 allowing, therefore, appropriate and robust 
comparisons. 
Stage-specific survival for colon cancer in Kuwait was similar to survival in the US for 
patients diagnosed at regional and distant stage. Due to low number of patients, it was not 
possible to estimate stage-specific survival for localised stage in Kuwait, however, the 
proportion of patients diagnosed at localised stage, which generally entails good prognosis, 
was substantially higher in the US (37.8%) than in Kuwait (10.7%). This difference in the 
proportion of patients diagnosed at early stage could partially explain the lower survival for 
all stages combined observed in Kuwait.     
For lung cancer, survival for all stages combined was lower in Kuwait (15.3%) than in the 
US (19.0%). Comparisons of stage-specific estimates were only possible for distant stage. 
The proportion of distant stage, however, constitutes the majority of lung cancer patients, 
which was similar in Kuwait and the US (47.6% and 50.9%, respectively). Stage-specific 
survival for distant stage was somewhat higher in Kuwait (8.0%) than in the US (4.8%). 
Therefore, the lower survival for all stages combined in Kuwait is probably attributable to 
differences in the proportion of patients diagnosed at localised stage, which was 
substantially lower in Kuwait (3.5%) than in the US (17.7%). Further investigation is 
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necessary to explain the higher survival for patients diagnosed at distant stage in Kuwait. 
While the introduction of targeted therapies has improved the treatment of advanced lung 
cancer,158 the very high cost of these treatments can limit their adoption and application.159 
In Kuwait, treatment is fully covered by the government, so financial limitations will probably 
have little effect on the usage of such therapies. In the US, medical insurance coverage can 
limit patients’ access to some of the less cost-effective treatments, particularly for patients 
with a poor prognosis. Therefore, to understand these differences in stage-specific survival, 
it would be necessary to assess the differences in the modality and access to treatment 
between the countries. 
For breast cancer, the difference in early stage at diagnosis may explain the lower survival 
observed for all stages combined between Kuwait (70.8%) and the US (88.6%). The lower 
proportion of women diagnosed at a localised stage could be due to lack of screening. Unlike 
the US, screening programmes for breast cancer were not available for women diagnosed 
during 2004-2009, since screening officially commenced in Kuwait in 2014.140 Differences 
in early stage diagnoses between the two countries could also be due to other factors such 
as the population’s awareness of early symptoms, knowledge of risk factors and access to 
timely diagnostic tests.   
Survival in Kuwait was also lower than in several other high-income countries.146 This could 
also be attributable to differences in diagnostic activity and the tendency towards later 
diagnosis in Kuwait. Differences in survival can arise due to several other reasons that 
require further investigation: prevalence of comorbidities; attitudes and behaviours towards 
treatment; differences in primary care systems; delays in access to treatment; and the 
efficacy of treatment. 
The small population of Kuwait limited our analyses, where the estimation of stage-specific 
survival by sex was not possible due to small number of patients available for analysis. The 
interpretation of stage-specific trends over the 14-year period 2000-2013 was also affected 
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by a high proportion of unknown stage, which was higher for patients diagnosed during 
2010-2013 than for patients diagnosed in earlier years.  
Conclusion 
Complete information on stage at diagnosis is required in order to assess the effectiveness 
of cancer control strategies. In Kuwait, the quality of and completeness of stage data can be 
improved in several ways, the most urgent of which is investing in the Kuwait Cancer 
Registry. This would include increasing the labour force, enabling the staff to cope with the 
increasing number of diagnoses, and continuously updating the staff’s knowledge and skills 
in order to adapt to changes in staging and coding guidelines. Another way would be to 
implement more systematic procedures for retrieving patients’ medical notes from different 
hospitals, particularly in the case of those receiving treatment abroad. Finally, investing in 
an electronic medical record system where all patients’ medical data would be stored 
electronically could improve the timelines substantially, and maximise efficiency to access 
patients’ data. 
This study supplements our previous knowledge on the effect of stage at diagnosis as a 
major determinant of outcome. Our study also shows that a low proportion of early-stage 
diagnoses could be a major contributing factor to lower survival in Kuwait than in other high-
income countries.  Investment in early detection, and increasing public awareness of cancer 





Table 6.1 Number of patients and distribution of SEER Summary Stage at diagnosis, 
by cancer and calendar period, Kuwaiti adults (15-99 years) 
Cancer site No. of cases
2000-2004 2005-2009 2010-2013 All periods
(n) (%) (n) (%) (n) (%) (n) (%)
Oesophagus
Localised 6 22.2 2 8.3 3 7.7 11 12.2
Regional 10 37.0 6 25.0 4 10.3 20 22.2
Distant 4 14.8 8 33.3 9 23.1 21 23.3
Unknown 7 25.9 8 33.3 23 59.0 38 42.2
Stomach
Localised 2 3.4 2 2.5 2 2.9 6 2.9
Regional 32 54.2 23 29.1 19 27.5 74 35.8
Distant 13 22.0 34 43.0 13 18.8 60 29.0
Unknown 12 20.3 20 25.3 35 50.7 67 32.4
Colon
Localised 25 10.6 34 10.5 25 7.2 84 9.3
Regional 162 68.4 151 46.5 110 31.8 423 46.6
Distant 39 16.5 99 30.5 90 26.0 228 25.1
Unknown 11 4.6 41 12.6 121 35.0 173 19.1
Rectum
Localised 19 22.4 18 13.9 13 11.3 50 15.2
Regional 48 56.5 53 40.8 30 26.1 131 39.7
Distant 9 10.6 31 23.9 17 14.8 57 17.3
Unknown 9 10.6 28 21.5 55 47.8 92 27.9
Liver
Localised 3 4.4 5 4.7 4 4.6 12 4.6
Regional 17 25.0 8 7.6 10 11.5 35 13.4
Distant 15 22.1 39 36.8 24 27.6 78 29.9
Unknown 33 48.5 54 50.9 49 56.3 136 52.1
Pancreas
Localised 2 3.5 4 4.4 1 1.1 7 2.9
Regional 23 40.4 15 16.5 15 16.3 53 22.1
Distant 22 38.6 49 53.9 45 48.9 116 48.3
Unknown 10 17.5 23 25.3 31 33.7 64 26.7
Lung
Localised 9 5.0 7 3.7 2 1.1 18 3.2
Regional 78 43.6 43 22.5 30 16.0 151 27.1
Distant 66 36.9 84 44.0 80 42.6 230 41.2
Unknown 26 14.5 57 29.8 76 40.4 159 28.5
Melanoma
Localised 1 20.0 1 14.3 1 16.7 3 16.7
Regional 2 40.0 1 14.3 1 16.7 4 22.2
Distant 1 20.0 3 42.9 0 0.0 4 22.2
Unknown 1 20.0 2 28.6 4 66.7 7 38.9
Breast
Localised 117 18.7 213 22.4 149 15.1 479 18.7
Regional 431 68.9 461 48.6 374 37.9 1266 49.4
Distant 47 7.5 126 13.3 102 10.3 275 10.7
Unknown 31 5.0 149 15.7 361 36.6 541 21.1
Cervix
Localised 19 30.7 15 25.4 6 14.3 40 24.5
Regional 28 45.2 20 33.9 11 26.2 59 36.2
Distant 5 8.1 3 5.1 2 4.8 10 6.1
Unknown 10 16.1 21 35.6 23 54.8 54 33.1
Ovary
Localised 10 16.1 10 10.9 3 4.5 23 10.4
Regional 30 48.4 23 25.0 18 26.9 71 32.1
Distant 16 25.8 36 39.1 19 28.4 71 32.1
Unknown 6 9.7 23 25.0 27 40.3 56 25.3
Prostate
Localised 27 23.3 43 25.4 61 27.2 131 25.7
Regional 36 31.0 21 12.4 15 6.7 72 14.2
Distant 33 28.5 53 31.4 36 16.1 122 24.0
Unknown 20 17.2 52 30.8 112 50.0 184 36.2
All cancers
Localised 240 15.2 354 15.9 270 11.9 864 14.2
Regional 897 56.7 825 37.1 637 28.2 2359 38.9
Distant 270 17.1 565 25.4 437 19.3 1272 21.0
Unknown 176 11.1 478 21.5 917 40.6 1571 25.9
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Table 6.2 Unstandardised net survival (NS, %) at one and 5 years since diagnosis, by SEER Summary Stage and calendar 
period; Kuwaiti adults (15-99 years) diagnosed during 2000-2013, followed to 31 December 2015 
Cancer Calendar 1-year net survival 5-year net survival
site period Localised Regional Distant Unkown stage All stages Localised Regional Distant Unkown stage All stages
NS(%) 95% Cl NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% CI NS(%) 95% Cl NS(%) 95% CI NS(%) 95% Cl NS(%) 95% Cl NS(%) 95% CI
Stomach 2000-2004 .. 53.2 35.7 - 70.6 40.6 14.6 - 66.7 46.6 18.7 - 74.6 50.8 37.7 - 63.9 .. 20.7 6.3 - 35.1 11.1 0.0 - 29.3 20.3 0.0 - 42.2 18.9 8.0 - 29.9
2005-2009 .. 70.4 51.8 - 88.9 44.7 28.2 - 61.2 40.3 19.6 - 61.1 52.6 41.5 - 63.6 .. 32.1 13.0 - 51.1 0.0 0.0 - 0.0 15.2 0.6 - 29.8 15.9 7.8 - 24.0
2010-2013 .. 59.0 37.1 - 80.8 30.9 7.5 - 54.4 55.2 38.7 - 71.7 51.6 39.7 - 63.5 .. 31.9 9.3 - 54.4 8.0 0.0 - 19.9 28.9 12.2 - 45.6 20.6 8.4 - 32.9
Colon 2000-2004 100.0 86.3 - 100.0 89.4 84.3 - 94.5 79.7 66.8 - 92.5 90.9 74.7 - 100.0 89.5 85.2 - 93.7 84.6 66.9 - 100.0 69.5 61.0 - 77.9 23.1 9.2 - 37.0 82.4 52.1 - 100.0 64.8 57.6 - 72.0
2005-2009 100.0 89.7 - 100.0 97.9 95.1 - 100.0 66.2 56.7 - 75.8 70.5 56.1 - 85.0 85.3 81.3 - 89.4 90.0 76.3 - 100.0 77.2 69.4 - 84.9 16.2 8.8 - 23.7 58.8 41.7 - 76.0 57.8 51.9 - 63.7
2010-2013 100.0 86.3 - 100.0 97.6 94.1 - 100.0 64.2 54.2 - 74.3 87.1 80.8 - 93.4 85.6 81.8 - 89.5 97.6 80.7 - 100.0 83.3 72.8 - 93.8 29.7 18.5 - 40.8 64.6 51.8 - 77.4 63.3 56.3 - 70.2
Rectum 2000-2004 89.4 74.0 - 100.0 95.0 88.1 - 100.0 .. .. 90.4 83.5 - 97.2 77.4 54.7 - 100.0 53.6 38.7 - 68.6 .. .. 60.7 49.2 - 72.3
2005-2009 100.0 81.5 - 100.0 97.6 92.4 - 100.0 75.6 60.3 - 90.9 93.2 83.8 - 100.0 92.4 87.3 - 97.4 99.0 88.5 - 100.0 70.2 55.9 - 84.5 19.9 5.2 - 34.7 61.5 41.8 - 81.2 60.8 51.3 - 70.3
2010-2013 100.0 75.3 - 100.0 100.0 88.4 - 100.0 59.8 36.9 - 82.7 94.4 87.5 - 100.0 91.8 86.3 - 97.2 86.6 65.8 - 100.0 76.3 55.0 - 97.7 23.5 3.0 - 44.0 72.7 45.1 - 100.0 67.0 51.7 - 82.3
Liver 2000-2004 .. 32.2 10.4 - 54.0 27.5 6.2 - 48.8 35.1 18.8 - 51.4 34.3 22.8 - 45.8 .. 7.2 0.0 - 18.0 6.9 0.0 - 17.4 9.7 0.0 - 20.0 11.4 3.5 - 19.2
2005-2009 .. .. 26.5 12.7 - 40.3 41.5 28.3 - 54.7 36.8 27.4 - 46.1 .. .. 4.4 0.0 - 10.5 19.3 8.2 - 30.4 12.4 5.8 - 19.1
2010-2013 .. 50.5 21.5 - 79.5 29.7 12.0 - 47.4 33.5 20.2 - 46.8 36.5 26.3 - 46.8 .. 0.3 0.0 - 1.0 0.0 0.0 - 0.0 11.1 1.7 - 20.6 8.3 1.8 - 14.9
Pancreas 2000-2004 .. 18.5 3.3 - 33.7 24.7 7.0 - 42.3 40.3 11.8 - 68.8 27.8 16.0 - 39.5 .. 9.2 0.0 - 20.0 5.0 0.0 - 12.6 10.1 0.0 - 24.9 11.2 3.1 - 19.3
2005-2009 .. 47.1 22.8 - 71.3 18.6 8.0 - 29.3 26.6 9.2 - 44.0 27.8 18.6 - 37.0 .. 6.9 0.0 - 17.4 4.5 0.0 - 9.9 4.4 0.0 - 11.1 8.2 2.5 - 13.8
2010-2013 .. 87.1 70.4 - 100.0 24.8 12.4 - 37.2 46.0 28.6 - 63.4 43.1 32.9 - 53.2 .. 12.1 0.0 - 28.3 7.0 0.1 - 14.0 25.0 6.0 - 44.1 15.3 6.8 - 23.8
Lung 2000-2004 .. 44.9 33.6 - 56.2 29.7 18.6 - 40.7 29.3 11.7 - 46.8 38.0 30.6 - 45.3 .. 17.1 8.1 - 26.2 6.8 0.7 - 12.8 8.9 0.0 - 19.9 13.7 8.2 - 19.3
2005-2009 .. 59.8 44.8 - 74.8 34.2 23.9 - 44.4 46.4 33.2 - 59.5 45.0 37.8 - 52.2 .. 23.6 10.0 - 37.2 7.6 1.8 - 13.5 17.8 7.1 - 28.5 15.7 10.1 - 21.3
2010-2013 .. 61.5 43.9 - 79.2 39.6 28.8 - 50.4 49.8 38.5 - 61.2 47.9 40.6 - 55.1 .. 17.7 2.3 - 33.0 6.7 0.4 - 12.9 19.0 7.5 - 30.5 13.9 7.6 - 20.3
Breast 2000-2004 99.0 96.7 - 100.0 96.8 95.0 - 98.7 85.5 75.2 - 95.9 87.6 75.9 - 99.2 96.0 94.3 - 97.7 88.6 81.4 - 95.7 76.7 72.3 - 81.2 44.5 29.6 - 59.3 66.7 48.8 - 84.6 76.1 72.4 - 79.9
2005-2009 99.3 97.7 - 100.0 98.0 96.5 - 99.5 80.1 73.0 - 87.1 94.3 90.3 - 98.4 95.4 93.9 - 96.8 98.2 94.4 - 100.0 80.8 76.8 - 84.9 30.7 22.5 - 39.0 78.3 70.3 - 86.4 77.7 74.7 - 80.7
2010-2013 99.7 98.4 - 100.0 97.8 96.1 - 99.6 79.3 71.3 - 87.3 97.3 95.4 - 99.2 96.2 94.8 - 97.5 95.0 89.2 - 100.0 85.4 80.2 - 90.7 38.2 27.9 - 48.6 89.0 83.7 - 94.2 82.6 79.3 - 85.9
Cervix 2000-2004 84.6 68.6 - 100.0 89.8 78.5 - 100.0 .. 80.2 56.4 - 100.0 84.4 75.2 - 93.6 54.4 31.9 - 76.9 59.3 40.6 - 78.0 .. 80.4 56.6 - 100.0 57.8 45.0 - 70.6
2005-2009 93.6 81.3 - 100.0 80.7 63.5 - 97.8 .. 90.7 78.1 - 100.0 88.7 80.4 - 97.0 88.4 71.5 - 100.0 68.3 47.1 - 89.4 .. 72.9 52.5 - 93.3 73.8 61.7 - 86.0
2010-2013 .. 91.1 74.9 - 100.0 .. 78.6 61.7 - 95.4 86.3 75.6 - 96.9 .. 94.7 77.9 - 100.0 .. 62.2 42.1 - 82.2 71.8 57.2 - 86.5
Ovary 2000-2004 100.0 69.2 - 100.0 77.3 62.2 - 92.4 56.7 33.7 - 79.7 .. 73.4 62.2 - 84.5 100.0 69.2 - 100.0 36.0 18.5 - 53.4 6.4 0.0 - 16.3 .. 38.9 26.3 - 51.5
2005-2009 100.0 69.2 - 100.0 95.8 87.6 - 100.0 64.4 48.8 - 80.0 74.9 57.2 - 92.6 79.0 70.5 - 87.4 81.1 57.3 - 100.0 54.2 32.6 - 75.8 23.1 9.5 - 36.7 43.4 22.5 - 64.3 42.6 32.0 - 53.3
2010-2013 .. 84.1 66.9 - 100.0 64.3 43.0 - 85.6 81.9 67.4 - 96.3 78.3 68.3 - 88.3 .. 61.6 37.6 - 85.6 0.1 0.0 - 0.2 60.6 41.9 - 79.3 40.3 22.1 - 58.5
Prostate 2000-2004 100.0 87.2 - 100.0 91.7 80.8 - 100.0 72.4 56.3 - 88.6 88.5 72.7 - 100.0 88.8 82.0 - 95.5 93.3 69.3 - 100.0 88.2 69.1 - 100.0 40.9 20.6 - 61.1 96.9 72.8 - 100.0 78.8 66.7 - 90.9
2005-2009 100.0 91.8 - 100.0 88.0 72.8 - 100.0 83.6 72.1 - 95.0 87.1 76.9 - 97.3 90.6 85.3 - 96.0 96.6 80.6 - 100.0 76.3 55.0 - 97.6 43.5 27.1 - 59.9 72.5 55.5 - 89.4 71.3 61.6 - 80.9
2010-2013 100.0 97.3 - 100.0 100.0 78.2 - 100.0 99.5 91.7 - 100.0 94.4 88.9 - 99.8 97.9 94.7 - 100.0 100.0 100.0 - 100.0 56.2 11.3 - 100.0 81.4 57.2 - 100.0 98.3 84.1 - 100.0 98.1 88.6 - 100.0
SEER: Surveillance, Epidemiology and End Results; CI: Confidence interval
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Table 6.3 Number of patients, SEER Summary Stage distribution (%) and age-
standardised net survival (NS,%), for adults in Kuwait (Kuwaiti) and the United 
States (all races), 2004-2009 
 
SEER SS: Surveillance, Epidemiology, and End Results Summary Stage; KW: Kuwait; US: 
United States; CI: Confidence interval 
  
Kuwait United States











Colon All stages 365 50.6 43.4 - 57.8 534,721 64.6 64.4 - 64.9
Localised (10.7) .. .. .. (37.8) 89.7 89.4 - 90.0
Regional (46.9) 73.0 66.8 - 79.3 (34.9) 70.2 69.8 - 70.6
Distant (29.9) 13.7 7.7 - 19.7 (19.3) 13.8 13.4 - 14.1
Unknown (12.6) .. .. .. (7.9) 49.4 48.6 - 50.2
Lung All stages 227 15.3 10.7 - 20.0 955,184 19.0 18.8 - 19.1
Localised (3.5) .. .. .. (17.7) 55.1 54.7 - 55.5
Regional (22.5) .. .. .. (23.4) 26.4 26.0 - 26.7
Distant (47.6) 8.0 3.8 - 12.2 (50.9) 4.8 4.7 - 4.9
Unknown (26.4) .. .. .. (8.0) 13.8 13.4 - 14.3
Breast All stages 1,092 70.8 64.0 - 77.6 926,271 88.6 88.4 - 88.8
Localised (21.9) 94.4 88.4 - 100.0 (59.1) 98.3 98.1 - 98.6
Regional (51.0) 75.7 67.2 - 84.3 (30.2) 82.3 81.9 - 82.7
Distant (12.5) 28.4 22.3 - 34.5 (5.2) 24.5 23.7 - 25.2









































































































































































































Figure 6.1 Trends in unstandardised net survival (NS, %) at 1 and 5 years, by SEER 







Figure 6.2 Distribution (%) of SEER Summary Stage for adults in Kuwait (Kuwaiti) 
and the United States (all races), 2004-2009 
 
SEER Summary Stage: Surveillance, Epidemiology, and End Results Summary Stage;  









Chapter 7: Research paper IV; Progress against cancer 
in Kuwait: Trends in incidence, survival and mortality 
_______________________________________________________________________________________________ 
 
Continuous monitoring of the cancer burden is essential to evaluate progress against 
cancer. However, for this evaluation to be comprehensive, trends in incidence, survival 
and mortality should be considered simultaneously.16,104,160  
Cancer incidence and mortality rates in Kuwait have been reported previously and, 
through this thesis, net survival for 18 of the most common cancers has also been 
estimated. However, survival in the context of incidence and mortality has not yet been 
assessed. 
This chapter addresses the final objective of this thesis: to evaluate the overall 
effectiveness of the Kuwaiti health care system in managing cancer during 2000-2013, 
using the three major cancer control metrics (incidence, survival and mortality). 
To achieve this, incidence, survival and mortality were estimated for all Kuwaiti adults 
(15-99 years) and children (0-14 years), diagnosed with one of the 18 most common 
cancers during 2000-2004, 2005-2009 and 2010-2013. Data on all malignant neoplasms 
and cancer deaths were obtained from the Kuwait Cancer Registry (KCR). Follow-up 
data on vital status of all registered cancer patients were obtained using our new 
approach to ensure that all deaths, irrespective of cause, were included [see Chapter 4]. 
To calculate incidence and mortality rates, population counts for Kuwaiti residents by 
year, age group and sex, were obtained from Kuwait’s Statistics Department at the Public 
Authority of Civil Information (PACI). Average annual incidence and mortality rates were 
produced, by calendar period, for each index cancer, age-standardised to the world 
standard population. Five-year net survival, corrected for background mortality using life 
tables of all-cause mortality by single year of age, sex and calendar period, was 





Evaluating incidence, survival and mortality revealed several patterns from which 
progress against cancer can be inferred. Patterns of increased survival combined with 
decreased incidence and mortality, explicitly imply progress in cancer control. However, 
other patterns showing improved prevention strategies, more effective removal of cancer 
precursors, enhanced early diagnostic activity, or better treatment and access to care, 











Research paper IV [unpublished]  
Progress against cancer in Kuwait: trends in incidence, 
survival and mortality 
_______________________________________________________________________________________________ 
Introduction  
The question of whether progress is being made in alleviating the cancer burden is of 
great interest to health professionals, policymakers and the general public alike. To 
assess progress is critical to determine whether primary prevention, diagnostic 
procedures and treatment modalities are efficient and effective. It is also crucial to 
evaluate whether the current cancer control policies are adequate, or if further changes 
in the cancer care system are required.  
The goal of primary prevention is to reduce the incidence of cancer and overall 
population morbidity. For those people who are eventually diagnosed with cancer, the 
goal of diagnosing the disease and treating it effectively is to reduce cancer deaths in 
the population, but evaluating progress based solely on mortality rates can be misleading 
for several reasons. Mortality rates are based on the selection and coding of the 
underlying cause of death, which can be affected by several factors: technological 
capabilities in detecting cancer that can affect the coding of cancer as the primary cause, 
changes in the selection and coding of the cause of death, and differences in accurately 
determining the underlying cause of death between individual physicians, different 
hospitals and regions.161 Also, in many countries, not all deaths are registered.162 
Moreover, mortality rates are not well suited to evaluate changes in the diagnostic 
capabilities or treatment of cancer, in a specific period of time. That is primarily because 
mortality rates are derived from deaths of patients who may have been diagnosed over 
many years in the past, and may not have received the same cancer management and 
treatment. The interpretation of mortality is also complex, since it is influenced both by 
the development of new cases (incidence) and the effectiveness of the health system in 





Population-based cancer survival is the appropriate indicator to assess the effectiveness 
of the cancer care system, since it encompasses all aspects of the healthcare system; 
from accurate and early diagnosis, to effective and prompt delivery of treatment.20 While 
increased survival is desirable, this might not always be indicative of true progress. For 
instance, an increase in survival can sometimes be observed as a result of early 
detection through improved diagnostic procedures or screening. However, if early 
detection is not coupled with effective treatment, the survival duration will increase but 
the mortality might not necessarily decease. This represents a situation where survival 
is increasing but no deaths are prevented or delayed.  
On the other hand, a lack of improvement in survival does not necessarily imply worse 
outcomes. For example, advanced detection procedures that enable the removal of 
malignant but pre-invasive or in situ tumours can shift the biological spectrum of invasive 
malignancies that are diagnosed towards more aggressive cancers: this can prompt 
survival trends to plateau or even decline, despite an overall reduction in incidence and 
mortality. Therefore, in order to achieve a comprehensive evaluation of the progress 
against cancer, trends in incidence, survival and mortality should be evaluated 
simulatanouely.16,104,160 
In Kuwait, incidence, survival and mortality have been previously assessed; however, 
there is no existing research evaluating these metrics simultaneously. In this study, we 
aim to evaluate progress against cancer in Kuwait via assessing survival in the context 
of incidence and mortality, for Kuwaiti children (0-14 years) and adults (15-99 years) 
diagnosed with one of 18 common cancers during 2000-2013. 
Materials and Methods: 
Data on all malignant neoplasms were obtained from the Kuwait Cancer Registry (KCR).  
The KCR is a national population-based cancer registry that collects and maintains high-
quality and complete incidence data.107 The International Classification of Diseases for 





Data were obtained for all Kuwaiti adults (aged 15-99) and children (aged 0-14) 
diagnosed during 2000-2013 with an index cancer: oesophagus, stomach, colon, rectum, 
liver, pancreas, lung, breast (women), cervix, ovary, prostate and melanoma of the skin 
in adults, in addition to brain tumours, leukaemias and lymphomas in both adults and 
children. To define the cancers, we used the anatomical site (topography) for all the solid 
tumours, and morphology for leukaemias, lymphomas, and melanoma of the skin. 
Data on cancer deaths occurring during 2000-2013 were also obtained from the KCR. 
The registry captures all cancer deaths in a specific year, through manual scanning of 
all “Death Announcements” at the National Centre for Health Information. An individual 
for whom the immediate cause or the underlying cause of death is indicated as cancer, 
is considered a cancer death.149 The most recent follow-up for vital status was performed 
in January 2018. 
Population counts for Kuwaiti residents for each year (2000-2013), by age group and 
sex, were obtained from Kuwait’s Statistics Department at the Public Authority of Civil 
Information. 
Complete and accurate data on follow-up for vital status (alive, dead, lost to follow-up) 
for all registered cancer patients, necessary to estimate the survival probability, were 
available as at 31 December 2015. Follow-up data were obtained using a combination 
of passive and active methods that ensured all deaths were included, irrespective of 
whether deaths were cancer-related.149  
Incidence and mortality rates were produced by calendar period (2000-2004, 2005-2009, 
2010-2013) for each of the index cancers. To avoid having small numbers of patients for 
analyses, average annual rates were estimated for both sexes combined, and expressed 
as the number of cancer diagnoses or cancer deaths per 100,000 person-years for 
adults, and per 1,000,000 person-years for children.  
When the number of incident cases or cancer deaths was fewer than 10, rates were not 





and the world standard population.163 For adults, age was categorised into 18 age 
groups: 0-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 
60-64, 65-69, 70-74, 75-79, 80-84, and 85 years and over. For children, the standard 
weights for the three age groups (0-4, 5-9, 10-14) were scaled up to ensure their sum 
equals to 1.164 The 95% confidence intervals (Cls) were also calculated.165  
Five-year net survival was estimated by calendar period (2000-2004, 2005-2009, 2010-
2013) for each index cancer, using the Pohar-Perme estimator,86 implemented with the 
program stns122 in Stata version 14.154 Survival was not estimated when fewer than 10 
patients were available for analysis. For adults, the International Cancer Survival 
Standard (ICSS) weights92 were used for age-standardisation, where age at diagnosis 
was categorised into 5 groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years and, for 
prostate cancer, 15-54, 55-64, 65-74, 75-84 and 85-99 years. For children, age-
standardisation was performed by assigning equal weights to the 3 age-specific 
estimates: 0-4, 5-9 and 10-14 years. Only unstandardised estimates were reported when 
standardisation was not possible. The 95% confidence intervals (CI) for all 
unstandardised and age-standardised estimates were derived assuming a normal 
distribution, truncated to the range 0-100. Confidence intervals were constructed using 
standard errors calculated using the Greenwood method.125 When no deaths or 
censorings occurred within 5 years, or if all patients died (survival probability 1 or 0), a 
binomial approximation was obtained for the upper and lower bound of the CI.88 
Results: 
During 2000-2013, survival increased for oesophagus, stomach, liver, pancreas, breast, 
prostate, brain (adults), lymphoid neoplasms, lymphoma (children), acute lymphoblastic 
leukaemia (children), and brain (children). Little or no change (less than 2%) was 
observed for rectal, lung, ovarian and cervical cancer, while survival declined for colon 





Considering survival in the context of incidence and mortality, the following patterns were 
observed: increase in survival combined with decreased incidence and/or mortality (liver 
cancer and childhood acute lymphoblastic leukaemia and lymphoma); decrease in 
incidence with little or no change in survival or mortality (lung, cervical and ovarian 
cancer); increase in survival with increased incidence or mortality (breast, prostate 
cancer and lymphoid neoplasms); little or no change in incidence, survival or mortality 
(rectal cancer); decrease in survival with increased incidence or mortality (colon cancer 
and myeloid neoplasms); and increase in survival with little or no change in incidence or 
mortality (oesophagus, stomach, pancreatic cancer, and brain tumours in adults and 
children) (Figure 7.1). 
Increase in survival, decreased incidence or mortality 
This pattern was illustrated for liver cancer, and for acute lymphoblastic leukaemia (ALL) 
and lymphoma in children.  
For liver cancer, unstandardised five-year net survival increased from 11.4% to 13.4% 
for patients diagnosed between 2000-2004 and 2010-2013, incidence fell from 5.5 to 3.6 
per 100,000 population and mortality decreased slightly (3.9 to 3.0 per 100,000).  
For ALL and lymphoma, survival increased from 76.1% to 88.4% and 93.0% to 96.3%, 
respectively. Incidence rates dropped from 47.3 to 39.9 per 1,000,000 for ALL, and from 
25.2 to 20.0 per 1,000,000 for lymphoma. Mortality rates were not available, because 
deaths due to lymphoblastic leukaemia (ALL) and lymphoma in children were very low 
(<10 patients). 
Decrease in incidence with little or no change in survival or mortality  
Between 2000-2004 and 2010-2013, this pattern was illustrated for lung, cervical and 
ovarian cancer.  
For lung and cervical cancer, incidence declined from 10.2 to 7.4 per 100,000 and from 





For cervical cancer, survival increased minimally (54.8% to 56.6%) and mortality 
remained the same, while for lung cancer, both age-standardised five-year survival and 
mortality rate remained stable (13.3% to 13.4% and 5.1 to 5.5 per 100,000, respectively).  
The same pattern was also observed for ovarian cancer between 2005-2009 and 2010-
2013, where incidence decreased (5.8 to 4.3 per 100,000), and age-standardised five-
year survival and the mortality rate remained stable (35.4% to 35.1% and 2.9 to 2.9 per 
100,000, respectively). 
Increase in survival, increased incidence or mortality 
For breast, age-standardised five-year survival increased from 68.3% to 75.2% between 
2000-2004 and 2010-2013, while incidence and mortality also increased, from 45.6 to 
58.7 per 100,000, and from 5.8 to 12.8 per 100,000, respectively.  
A similar pattern appeared for prostate cancer patients diagnosed between 2005-2009 
and 2010-2013, where increases were observed in survival (71.9% to 84.0%) and 
incidence (16.0 to 21.5 per 100,000); however, unlike for breast cancer, mortality for 
prostate cancer decreased during 2005-2013 (from 4.9 to 3.4 per 100,000). For lymphoid 
neoplasms, slight increases between 2000-2004 and 2010-2013 were observed in 
incidence (15.5 to 16.7 per 100,000) and mortality (3.5 to 4.3 per 100,000), while the 
increase in survival was more substantial (71.9% to 84.0%). 
Little or no change in survival, incidence or mortality 
This pattern was reflected for rectal cancer between 2000 and 2013: little change in any 
of the three age-standardised metrics was observed (1% or less change in survival and 
0.5 or less per 100,000).  
For melanoma, incidence, survival and mortality were not estimated, due to small 
numbers of patients or deaths, but the number of incident cases and deaths remained 







Decrease in survival, increased incidence or mortality 
This pattern was most evident in colon cancer and myeloid neoplasms.  
For colon cancer, survival decreased (from 64.8% to 58.5%) between 2000-2004 and 
2010-2013, and incidence increased slightly (from 11.4 to 12.6 per 100,000), while 
mortality more than doubled (2.3 to 5.4 per 100,000). In contrast, a different pattern was 
observed for colon cancer between 2005-2009 and 2010-2013: survival increased (from 
50.2% to 58.5%), while incidence and mortality rates increased slightly (from 11.4 to 
12.6, and 4.1 to 5.4 per 100,000, respectively). 
For myeloid neoplasms in adults, a similar pattern was observed between 2000-2004 
and 2010-2013: survival decreased from 38.6% to 25.6%, while incidence and mortality 
increased slightly (3.5 to 4.3 per 100,000 and 1.4 to 2.2 per 100,000, respectively). 
Between 2005-2009 and 2010-2013, however, the three metrics changed relatively little: 
survival changed from 24.0% to 25.6%, incidence from 4.1 to 4.9 per 100,000 and 
mortality from 1.9 to 2.2 per 100,000. 
Increase in survival,  little to no change in incidence or mortality 
This pattern was observed for oesophagus, stomach, pancreatic cancer, and brain 
tumours (adults and children). While survival increased between 2000 and 2013, for all 
these cancers, incidence and mortality rates changed minimally (1 or less per 100,000). 
Discussion: 
This study presents the first evaluation of trends in survival during 2000-2013 for 18 
common cancers in Kuwait, interpreted in the context of incidence and mortality. To 
evaluate all three metrics simultaneously allows for a more insightful assessment of 
cancer control strategies, highlighting patterns in incidence, survival and mortality that 
can show whether progress is truly being achieved.16,166 
Between 2000-2004 and 2010-2013, survival increased for most cancers: oesophagus, 





and acute lymphoblastic leukaemia (children). However, survival decreased for patients 
diagnosed during 2000-2004 and 2005-2009 for all cancers, with the exception of liver, 
lung, breast, lymphoid neoplasms and brain (children). This decline was attributed 
primarily to improvements in the registry’s data quality.146 Over the 14-year period (2000-
2013), the percentage of patients lost to follow-up, as well as those registered only from 
a death certificate (DCO) or detected solely at autopsy, gradually decreased, ultimately 
reaching 0% for almost all cancers by 2010-2013. In survival analyses, DCOs are 
excluded because follow-up information for these patients is unavailable. DCO 
registrations also tend to comprise patients diagnosed with more lethal cancers, or with 
cancers diagnosed at an advanced stage. Therefore, improved registration practices 
over the years, resulting in fewer exclusion of DCOs, can also lead to an apparent decline 
in survival.129 
The increases in survival between 2005-2009 and 2010-2013 for most cancers, despite 
continual improvement in data quality, could therefore be indicative of advances in the 
effectiveness of the healthcare system in managing and treating cancer. These 
increases in survival also coincide with the establishment of the five-year cancer care 
partnership between the Kuwait Cancer Control Centre (KCCC) and the Toronto 
University Health Network (UHN). The latter commenced in January 2011, with the goal 
of improving the health services for cancer patients in Kuwait.167 To monitor survival of 
patients diagnosed after the end of the partnership will be critical to assess its effect on 
the healthcare system. 
Mortality rates were relatively stable for most cancers between 2000-2004 and 2010-
2013, with the exception of colon and breast cancer, where mortality increased (2.3 to 
5.4 per 100,000, and 5.8 to 12.8 per 100,000, respectively). This lack of decrease in 
cancer deaths over the years, despite increased survival for many cancers, could be 
indicative of incomplete death registration in earlier years, particularly during 2000-2004. 
As with the registration of incident cases, the quality and completeness of death 





more standardised and timely, better coordinated with hospitals and vital statistics 
offices, and less susceptible to variations in attributing the deaths as “due to cancer”. 
The latter, however, are dependent on whether the selection of causes leading to the 
death are coded correctly by physicians.149 Therefore, incomplete death ascertainment, 
improper sequencing of causes of death, and differences in certification of cancer as the 
underlying cause, could collectively constitute a problem in calculating cancer mortality 
rates. This reinforces the argument against using mortality rates as the sole indicator of 
progress. 
The combination of increased survival with decreased incidence and mortality presents 
an explicit pattern of progress against cancer. This pattern was shown for liver cancer, 
and childhood acute lymphoblastic leukaemia (ALL) and lymphoma. For liver cancer, 
some of the main precursors are chronic infections with hepatitis B (HBV) or C virus 
(HCV).168 Therefore, this decrease in incidence of liver cancer in Kuwait, and slight 
increase in survival (2%), could be due to improved vaccination and medical 
interventions (e.g. new antiviral therapies for acute HCV and chronic HBV or HCV 
infections),168,169 increased public health knowledge of preventing transmission and 
infection, and enhanced detection or access to care. 
For lymphoma and acute lymphoblastic leukaemia in children, progress was mainly 
attributable to the major advances in the treatment of ALL in children, and lymphoma in 
both adults and children over the past decades.170,171 However, the same cannot be 
implied for myeloid neoplasms in adults, where only slight increases in survival were 
observed between 2005-2013 (24.0% to 25.6%). This could be partly because improved 
management of ALL pertains mostly to younger patients, where adults with ALL trend to 
have worse outcomes than children, due to underutilisation of chemotherapy regimens 
associated with older age.172,173 Moreover, our definition of myeloid neoplasms in this 
study includes other subtypes such as acute myeloid leukaemia (AML), which are 





Decreases in incidence, observed for lung, cervical and ovarian cancer, are also likely 
to indicate progress. This is primarily due to the fact that although survival increased 
minimally for cervix (54.8% to 56.6%) and remained relatively constant for lung and 
ovary, a decline in incidence generally reflects that fewer people are being diagnosed 
with the disease. This could be due to lower prevalence of risk factors. In the case of 
lung cancer, introducing tobacco control initiatives such as the implementation of national 
tobacco control programmes, smoking bans, smoking cessation support, and decreasing 
the affordability of cigarettes,174 could have contributed to the decline in incidence rates. 
For ovarian cancer, the reduced incidence could reflect the uptake of oral contraceptives 
or the decline in usage of menopausal hormone therapies,175 both of which are known to 
reduce the risk of ovarian cancer.176  
Declines in incidence can also reflect early diagnostic activity. In the case of cervical 
cancer, cancer precursors or pre-malignant tumours are detected through pap smears, 
and are subsequently removed. This leads to an increase in in situ tumours [data not 
shown] and fewer invasive malignancies, without necessarily improving survival. 
For breast cancer, incidence, survival and mortality increased between 2000-2004 and 
2010-2013, while for prostate cancer, incidence and survival increased, but mortality 
remained relatively constant. Similar increases in incidence and survival for breast and 
prostate were also observed in Europe,177 and were partly attributed to early diagnosis: 
mammography screening programmes for breast cancer, and widespread use of 
prostate-specific antigen (PSA) testing for prostate cancer. These early diagnostic 
procedures can sometimes bias survival estimates: lead-time bias (increases survival 
through bringing forward the time of diagnosis without postponing the time of death), 
length bias (increases survival by preferential detection of slow-growing tumours or 
tumours with good prognosis), and “over-diagnosis” (detecting tumours that would never 
have progressed to cancer during the patient’s expected lifetime, or progressed so slowly 
that the patient would have died from other causes without experiencing symptoms that 





for prostate cancer than breast cancer,104 implying that the increased survival for prostate 
cancer does not necessarily reflect true progress. However, between 2005-2009 and 
2010-2013, increases in prostate cancer survival in Kuwait were coupled with slight 
decreases in mortality. This decrease, despite a continuous increase in incidence, could 
suggest possible therapeutic improvements or better management and access to cancer 
care.  
In Kuwait, the national mammography screening programme for breast cancer was not 
operational for patients diagnosed during 2000-2013. This suggests that, in addition to 
opportunistic screening, other factors could be responsible for the increasing incidence, 
such as delayed childbirth, fewer children and increased obesity.178,179 The obesity 
epidemic in Kuwait is striking,180 and could certainly influence the incidence of obesity-
related cancers. These factors could also have contributed to the increased mortality 
rates observed in Kuwait, and most Asian countries, which conflict with the decreases in 
breast cancer mortality observed in North America, Western Europe and Oceania.178 In 
contrast, the increased survival seen in Kuwait could therefore be attributed to an 
increase in early-stage diagnosis, providing better treatment opportunities and more 
effective and individualised approach to treatment,181 and increased awareness and 
knowledge of Kuwaiti women with regard to breast cancer warning signs.182 
Between 2000-2004 and 2010-2013, colon cancer incidence increased slightly, survival 
decreased, and mortality increased substantially. This pattern, however, was not 
consistent throughout the 14-year period. Between 2005-2009 and 2010-2013, 
incidence, survival and mortality all increased. The increases in incidence and mortality 
could be due to higher prevalence of lifestyle-related risk factors (diet high in fat, high 
meat consumption, physical inactivity, obesity).183 However, although these factors are 
highly prevalent in Kuwait,184 the incidence rates during 2000-2013 increased only 
slightly (11.4 to 12.6 per 100,000). This could suggest greater early diagnostic activity, 
for instance, the widespread use of advanced endoscopy procedures − not necessarily 





benign tumours, and can result in decreased incidence of invasive malignancies. This 
can counterbalance the high prevalence of risk factors, leading to a minimal increase in 
incidence. The increased survival for colon cancer in Kuwait could therefore be due to 
diagnosis of early-stage tumours or better treatment.  
For cancers where survival increased but there was no substantial change in incidence 
or mortality, increases in survival could be due to various reasons: earlier detection via 
endoscopy (stomach cancer),185 enhanced diagnostic imaging (pancreatic cancer),186 
better therapeutic practices, or better access to cancer care. Moreover, in Kuwait, more 
complete death registration since 2000-2004 could have contributed to the lack of 
decrease in mortality for many cancers between 2000-2004 and 2010-2015, despite 
increases in survival. Continuous surveillance of incidence, survival and mortality should 
therefore be maintained in the future, in order to monitor where mortality eventually 
decreases as a result of increased survival.  
Due to Kuwait’s small population, small numbers of patients restricted the estimation of 
some cancer metrics (e.g. melanoma in adults, childhood mortality). Separate analyses 
by sex, and age-standardisation of all the survival estimates was also not possible for 
some cancers, hindering our interpretation of trends throughout the period 2000-2013.  
Conclusion 
This evaluation of survival alongside incidence and mortality has provided a more 
comprehensive overview of progress against cancer. In Kuwait, the observed progress 
might be associated with implantation of preventive strategies (e.g., tobacco control 
initiatives with lung cancer, or improved HBV vaccination for liver cancer), removal of 
precursor lesions (e.g., pap smears for cervical cancer), early diagnostic activity (e.g., 
mammography for breast cancer), and better treatment (e.g., lymphoma, childhood ALL 
and colon cancer). However, the increase in the incidence of lifestyle-related cancers 
(e.g., breast and colon cancer) suggests the need for more public health prevention 





assess progress against cancers where survival has not improved, or even declined. 
Finally, this study accentuates the importance of strategic and continuous evaluation of 







Table 7.1 Age-standardised incidence (ASIR) and mortality rates (ASMR) per 
100,000 per years and age-standardised 5-year net survival (NS,%), Kuwaiti 








Figure 7.1 Age-standardised incidence rate (ASIR), age-standardised 5-year net 
survival (NS,%) and age-standardised mortality rate (ASMR), 2000-2013 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 8: Discussion, perspectives and conclusion 
_______________________________________________________________________________________________ 
8.1  Summary 
Evaluation of population-based cancer survival is crucial to assess the effectiveness of 
the cancer care system in a country or region. In Kuwait, population-based cancer 
survival has never been evaluated. In this thesis, a new approach was implemented to 
obtain reliable and complete follow-up data on the last known vital status for all Kuwaiti 
cancer patients. This is essential to obtain robust estimates of population-based survival. 
Net survival was then estimated up to 5 years after diagnosis for 18 common cancers. 
Further analyses of survival by stage at diagnosis were performed, to provide a deeper 
understanding of cancer survival in Kuwait. Finally, an overall assessment of progress 
against cancer was performed, using the three main cancer control metrics: incidence, 
survival and mortality. 
8.1.1 First objective 
To enable the estimation of population-based survival in Kuwait for the first time, the 
initial objective was to obtain reliable and complete follow-up data on the last known vital 
status for all Kuwaiti cancer patients registered in the Kuwait Cancer Registry (KCR) 
during 2000-2013. To achieve this, the implementation of a novel approach to obtain 
follow-up data on vital status was required. Unlike the traditional method used by the 
Kuwait cancer registry, this new approach ensured that all deaths among registered 
cancer patients were ascertained, irrespective of the cause of death. 
This approach proved to be highly effective, resolving the vital status and, if dead, the 
date of death, for almost all (98.3%) patients whose vital status had previously been 
unknown. This allowed complete data on follow-up for vital status to become available 
for all Kuwaiti cancer patients, for the first time. 
Implications and perspectives 
The Kuwait cancer registry is a long-standing registry, established in 1971,15 that 
maintains high-quality data on cancer patients.107 However, since the registry’s 





status has been restricted to deaths due to cancer. This meant that information on 
patients who died due to other causes was not captured. Therefore, these patients were 
considered to be alive. While it is plausible that most cancer patients’ deaths would be 
due to their cancer - especially those diagnosed with more lethal types of cancer - many 
patients die from causes other than cancer. This is particularly important in our case, 
where about 40% of the cancer patients included in this thesis are diagnosed with breast 
and prostate cancer, which generally entails a good prognosis. Moreover, in Kuwait, 
injuries primarily from car accidents account for almost as many deaths as cancer.94 
Therefore, there is a great chance that cancer patients in Kuwait could die from other 
causes, and those deaths would not be recorded by the registry. 
Our approach was implemented with the coordination of different ministerial agencies 
and departments. Electronic linkages were not possible, since this required formal 
ministerial agreements, which it has not yet been possible to obtain. We therefore used 
semi-manual methods whereby employees at the Central Record Department for Birth 
and Death of the Ministry of Health, manually entered each patient’s national 
identification (Civil ID) number into the databases to extract the desired information. 
However, although the sources of information utilised were considered reliable, and the 
process proved to be highly effective in obtaining data on follow-up for vital status, the 
whole process was very time-consuming and required numerous data quality checks. 
For this reason, the recommendation is for this approach to be performed electronically 
and routinely in the future, through a series of steps: 
1) Submission of a proposal to the Director of the Kuwait Cancer Control Center 
(KCCC), highlighting the results of this research (Chapter 4) and requesting 
systematic provision (preferably annual) of follow-up data to the Kuwait 
Cancer registry (KCR). 
2) Attainment of approval by the Minister of Health in Kuwait. 
3) Establishment of a formal agreement between the Ministry of Health and the 





all patients registered in the KCR by the end of a given year to be 
electronically linked with the vital status information available in the PACI 
database. The date of death for the deceased, as well as additional variables, 
such as sex and date of birth, should be retrieved to confirm that correct 
linkages were performed.  
 
The most evident benefits of implementing this approach would be gained by the KCR. 
For instance, from a practical perspective, this approach can substantially decrease the 
cancer registry’s workload, thus enabling the staff to focus their efforts elsewhere. The 
KCR’s current procedures to obtain data on follow-up for vital status involve manual 
scanning of all death announcements in a given year for the entire country. This process 
is time-consuming and prone to human error. With the electronic implementation of this 
approach, the cancer registry staff’s time could be better spent on improving the quality 
of the data, as well as the variables included in their data base, by collecting additional 
information, such as TNM (Tumor, Nodes, Metastasis) stage, treatment and 
comorbidities. 
As the KCR is a major source of information on cancer patients in the country, the 
implementation of this approach will enable accurate and prompt production of reports 
on cancer patients’ vital statistics at any given time. Many researchers, clinicians, 
organisations and policy-makers also use data from the cancer registry for different 
reasons. Therefore, the data provided on vital status must be complete and up to date, 
in order to be utilised and interpreted correctly. 
In terms of international impact, this approach can offer guidance to other registries, 
particularly those in neighbouring countries with similar administrative systems. To use 
the same concepts and framework adopted in Kuwait could help them to update and 
improve their procedures to collect data on follow-up for vital status. 
It is important to note, however, that without the systematic implementation of this 





Kuwait. The systematic implementation of this approach is therefore crucial to allow 
continuous monitoring and evaluation of the healthcare system in the country.  
8.1.2 Second objective 
Upon obtaining all the required data, the second objective of this thesis was to produce 
net survival estimates up to 5 years since diagnosis, for 18 common cancers, that can 
be monitored and compared internationally, in order facilitate the assessment of cancer 
control in Kuwait. 
An overview of trends in population-based cancer survival was presented for Kuwaiti 
patients diagnosed during 2000-2013, with the following index cancers: oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate 
and melanoma of the skin in adults, in addition to brain tumours, leukaemias and 
lymphomas in both adults and children. 
Although population-based 5-year net survival estimates for the same time period were 
also published for Kuwait in the third cycle of the CONCORD programme,81 it is important 
to note that this was due to the work of this thesis (first objective), which made complete 
data on follow-up for vital status available, and therefore enabled Kuwait to participate 
for the first time. The inclusion of the Kuwaiti data in the CONCORD programme has 
benefited this thesis, allowing survival estimates in Kuwait to be compared with other 
high-income countries. 
Through this objective, survival estimates beyond those published in CONCORD-3 for 
Kuwait were presented and discussed. For instance, estimates by sex were produced, 
as well as shorter-term survival estimates (at 1 and 3 years), which are important for 
more lethal cancers. The results revealed that cancer survival improved for most Kuwaiti 
adults and children during 2000-2013, with women generally having a more favourable 
prognosis than men. The discussion, however, did point towards the need for further 





explain Kuwait’s generally low survival in comparison with other high-incomes countries 
included in CONCORD-3. 
Implications and perspectives 
Cancer survival is crucial to measure how the healthcare system manages cancer in a 
specific region and calendar period. Survival in Kuwait was estimated by using complete 
and high-quality data, as well as the most up-to-date, unbiased, non-parametric 
methods. These results can therefore be of use to various groups: academics and 
researchers, governmental organisations, health awareness campaigns, cancer 
charities and health policy-makers, as well as the general public.  
These estimates can also contribute to the planning of cancer care services, and feed in 
to the national cancer plans. In Kuwait, the KCCC has implemented a strategic cancer 
plan for 2013-2018. One of its long-term goals is to “measure and improve outcomes”, 
which is proposed to be assessed through measuring “disease control rates and 
survival”. Age-standardised net survival estimates up to 5 years for 2010-2013 could 
serve as the basis to achieve this goal. Survival estimates for patients diagnosed during 
2014-2018 can subsequently be obtained and compared with those for patients 
diagnosed in 2010-2013. These survival estimates can also serve as a basis for more 
specific goals targeting survival in future cancer control plans; for example, using the 
results to target certain cancers where no improvements have been observed, or to help 
specify a survival target to be reached, based on the most recent survival estimate for 
that cancer. 
Moreover, the survival estimates published in this thesis can be used to assess 
interventions aimed at improving cancer care services, such as the KCCC’s 5-year 
partnership with the Toronto University Health Network (UHN), initiated in 2011.187 One 
of the primary goals of this partnership was to improve clinical management and services 
through the creation of specialised multidisciplinary teams for the delivery of disease-





to the best international guidelines. The increase in survival observed for most cancers 
between 2005-2009 and 2010-2013 could therefore point towards improvements 
resulting from this partnership. However, further monitoring of survival is essential for a 
more comprehensive evaluation of the success of this partnership, through comparing 
the cancer control metrics and survival of patients diagnosed before and after the launch 
of this partnership. 
The ability for Kuwaiti cancer patients to receive cancer treatment abroad also suggests 
the need to quantify the proportion of patients who travel abroad in order to understand 
the effect of different therapeutic geographies on the cancer care system in Kuwait. 
Further sub-group analyses comparing patients who stay in Kuwait for the totality of their 
treatment to patients who receive partial or complete treatment abroad should also aid 
the interpretation of the healthcare system in Kuwait. Assessment of the differences in 
the healthcare systems is also crucial in interpreting the findings.  
8.1.3 Third objective 
The third objective was to assess the distribution of stage at diagnosis and stage-specific 
survival for 12 cancers in Kuwait, for which Surveillance Epidemiology and End Results 
(SEER) Summary Stage data were available. According to the results corresponding to 
my second objective, improvements were shown for many cancers in Kuwait, but 
differences in survival were observed between Kuwait and other high-income countries. 
In order to understand these disparities better, the stage distribution and stage-specific 
survival for colon, lung and breast cancer were compared between Kuwait and the United 
States.  
This objective aimed to illustrate, for the first time in Kuwait, the diagnostic activity for 12 
cancers over a 14-year period. The results revealed that early diagnosis was generally 
low, and that survival was progressively lower with more advanced stage. However, the 
difference between earlier and more advanced stages was more substantial for some 





indicated that late-stage diagnoses are a major contributing factor to lower survival in 
Kuwait. 
Implications and perspectives 
Stage at diagnosis is a major determinant of cancer outcome. The pattern of survival by 
stage at diagnosis can illustrate where improvements and investments can and should 
be made. The results of this objective, therefore, not only provide a more thorough 
evaluation of survival in Kuwait, but may also have wider uses and implications, as 
explained below. 
A major outcome was highlighting Kuwait’s cancer diagnostic activity. Early diagnosis 
was generally less common than in the US for all cancers, including those for which early 
diagnostic tests are available. However, via comparing stage-specific survival between 
Kuwait and the US, the results showed that survival could be improved if more cancers 
were diagnosed at an earlier stage. This highlights the urgent need for initiatives aiming 
to improve early detection in Kuwait. Including early diagnosis as a goal in the KCCC’s 
future cancer control strategic cancer plan, where changes can be assessed and 
monitored, should be the first step towards improvement. 
Introducing national screening programmes for a few cancers could also substantially 
improve early diagnosis. While Kuwait has the financial resources to implement such 
programmes, further assessments are necessary to determine whether the health 
infrastructure and the diagnostic capabilities are adequate to enable the implementation 
of successful long-term screening programmes. Currently, there is only one national 
screening programme available in Kuwait, for breast cancer, initiated in 2014.140 Results 
on the uptake of screening have not yet been reported, but the distribution of stage-
specific survival would provide a valuable assessment of its success. Breast cancer 
survival should be continually monitored over the next 5-10 years, in order to evaluate 





Furthermore, Kuwait’s low level of activity to achieve early diagnosis also suggests the 
need for future investigations to identify other factors contributing to delayed diagnosis. 
For instance, low early detection could be due to Kuwaiti women’s lack of awareness of 
cancer risk factors or the early symptoms of cancer, or even due to the cultural stigma 
and perception of being diagnosed with cancer. All these factors should be addressed in 
order to understand better their impact on early diagnosis. It is also crucial that the results 
presented in this objective are shared beyond the context of KCCC and academia, 
reaching cancer awareness organisations in the country, such as Cancer Awareness 
Nation (CAN).188 Increased awareness and promotion of earlier diagnosis of cancers for 
which screening is available could be achieved through CAN’s initiatives. 
Finally, in addition to the importance of diagnosis at an early stage, the results also 
revealed that incomplete data on stage present a major limitation to monitoring trends in 
cancer survival by stage in Kuwait. The proportion of patients with unknown stage at 
diagnosis has actually increased in recent years, reaching about 40% during 2010-2013. 
This restricted the evaluation of trends in survival by stage during 2000-2013, and will 
probably prevent future evaluations, unless the recording of stage at diagnosis is 
improved. Further enhancement in the collection of stage data is therefore crucial. This 
can be achieved through encouraging clinicians to systematically record TNM stage at 
diagnosis, investing in the KCR, improving the management of patients’ files, and 
allowing better access to patients’ data via the implementation of an electronic medical 
record system in the KCCC. 
In conclusion, although late stage at diagnosis partly explains the lower survival in Kuwait 
than in other high-income countries, it is undoubtedly not the only factor. The prevalence 
of comorbidities, outmoded attitudes and behaviours towards treatment, differences in 
primary care systems, delays in diagnosis or treatment, as well as the efficacy of 





8.1.4 Fourth objective 
The fourth and final objective of this thesis was to evaluate the overall health care system 
in Kuwait in managing cancer patients, using the three major cancer control metrics: 
incidence, survival and mortality. 
A comprehensive overview of the progress against cancer in Kuwait was presented for 
the first time, for all Kuwaiti cancer patients diagnosed with one of 18 common cancers 
over a 14-year period. The results revealed patterns of progress for the majority of 
cancers in Kuwait. The observed progress was probably due to the following factors: 
implementation of prevention strategies, removal of cancer precursors, early diagnostic 
activity, and better treatment and access to care.  
Implications and perspectives 
Cancer control initiatives generally focus on three main goals: a) reducing the number of 
people diagnosed with cancer (incidence); b) extending the length of cancer patients’ 
lives following diagnosis (survival); and c) reducing the number of cancer deaths 
(mortality).   
Throughout the thesis, emphasis was placed on the importance of population-based 
survival as a means of assessing improvements in cancer care. Evidence against the 
use of mortality rates as the sole indicator of progress was as also given (Section 1.5). 
While working on this fourth objective, the reliability of the mortality rates in Kuwait was 
found to be affected by several issues, such as incomplete death ascertainment, 
improper sequencing of causes of death, and differences in selection of cancer as the 
underlying cause. The results, therefore, are in agreement with the current literature, 
which supports the use of survival as the best evaluator of the healthcare system.21,83 
The results of this objective have also provided examples supporting the use of all three 
cancer metrics simultaneously to evaluate cancer progress. For instance, progress 
would not have been inferred for some cancers in Kuwait where survival did not increase. 





more comprehensive evaluation of progress was obtained, providing information on 
whether the number of people diagnosed with the disease decreased or fewer patients 
were dying from it.  
In the case of Kuwait, these results have revealed that progress has been achieved for 
many cancers over the years. Progress was more clearly illustrated in the most recent 
years (2010-2013), coinciding with the country’s increased investment in improving 
cancer care services through international collaborations. The results also point towards 
improvements in reducing risk factors and providing earlier diagnosis for some cancers. 
However, the results also showed that for some cancers, increased risk factors could be 
contributing to more people being diagnosed. This, therefore, points to the need of more 
public health intervention and awareness programmes targeting specifically those 
cancers. 
The results presented here, as well as the method used to evaluate progress, should 
also be implemented in Kuwait in a systematic manner. For instance, in the KCCC’s 
strategic plan 2013-2018, measuring “disease control rates and survival” is included as 
a method of evaluating one of the long-term goals of improving outcome. However, 
currently, cancer incidence is the only metric systematically produced and assessed by 
the KCR. While mortality rates are produced annually by the National Centre for Health 
Information for Kuwaitis, they are currently reported for all cancers combined, and they 
cannot be used to assess changes in cancer control for each type of cancer. However, 
population-based survival had not previously been reported for the major cancers, apart 
from the publications arising from this research (Chapter 5). This indicates that, although 
the need to measure and assess the cancer metrics is included in the national cancer 
control plans, the necessary procedures to ensure their production are not yet in place. 
In order for all three metrics to be assessed, legislative regulations need to be 
established that would ensure the systematic production of these metrics. Their 






8.2  Limitations 
The main limitation affecting most of our objectives was the small number of patients 
available, predominantly due to Kuwait’s low population. This limited the production of 
more detailed survival estimates for all cancers, such as survival by sex, or long-term 
survival, for example at 10 years. The small number of patients also led to less reliable 
estimates for the rarer cancers, and prevented age-standardisation of some estimates, 
particularly for stage-specific analyses.  
In terms of mortality, the small number of diagnoses also implied a low number of deaths; 
this inhibited the production of mortality rates for some cancers, particularly for children. 
Incomplete death registration in the early calendar periods in Kuwait also inhibited robust 
evaluation of mortality trends for all cancers. That said, mortality rates were used as a 
supplement to survival in evaluating trends, and not as the main measure of interest. 
However, the completeness of death registrations has improved over the years, both in 
the cancer registry and in the country’s civil registration and vital statistics sytem,189 and 
therefore, mortality rates presented for the most recent years (2005-2013) were more 
robust.   
The inability to include in this thesis data for non-Kuwaiti cancer patients residing in 
Kuwait also presented a limitation. While most non-Kuwaiti patients would be diagnosed 
in Kuwait, and therefore should have complete diagnosis information, data on follow-up 
for their vital status would be substantially incomplete. That is because non-Kuwaitis 
primarily consist of expatriate labourers employed with short contracts who would 
generally return home upon becoming critically ill. The Public Authority for Civil 
Information, where vital status was ascertained for Kuwaiti patients, cannot be used to 
track the vital status of persons who have left the country. Thus, to obtain complete and 







8.3  Action plan 





1) Improving data: a) To establish an electronic linkage between the Kuwait 
Cancer Registry (KCR) and the Public Authority of Civil 
Information (PACI) in order to enable the ascertainment 
of all deaths among registered cancer patients, 
regardless of the cause of death, and the systematic 
update of vital status for cancer patients in Kuwait. 
 
b) To implement an electronic health record system in the 
Kuwait Cancer Control Centre (KCCC) to improve the 
completeness of ascertainment of data on stage at 
diagnosis in the KCR. 
 
c) To introduce new policies and procedures to ensure 
patients’ information and medical history is sent to the 




2) Potential cancer 
policy developments: 
a) To introduce a bowel cancer screening programme into 
Kuwait, to improve early diagnosis.  
 
b) To investigate reasons for delays in diagnosis in Kuwait 
through conducting a case-control study, comprising 
‘late’-diagnosed patients and controls ‘non-late’ 
diagnosed patients (controls).  
 
c) To develop a questionnaire to explore relevant 
explanatory factors such as ignorance, fears, cultural 
barriers, promptness in receiving early diagnostic 
procedures and social perceptions of the effectiveness 








8.4  Conclusion 
Cancer is a major cause of death in Kuwait and the measures involved in the fight against 
it are numerous and complicated, ranging from prevention and diagnosis, to prompt and 
effective treatment and care. Population-based cancer survival is a valuable measure of 
the effectiveness of the health system in managing cancer, and improvement in survival 
is vital for extending patients’ lives. However, in order to make valid assessments of 
survival, complete and high-quality data on diagnosis and follow-up are required on all 
cancer patients. 
This thesis has, for the first time, outlined and implemented an effective method to obtain 
complete data on follow-up for vital status, for all cancer patients in Kuwait, enabling 
robust estimation of population-based net survival for 18 cancers. This also enabled 
Kuwait to participate in the CONCORD programme, the largest programme for 
surveillance of population-based cancer survival world-wide, allowing international 
comparisons between survival in Kuwait and other countries. 
Survival estimates up to 5 years after diagnosis were produced for patients diagnosed 
over a period of 14 years, 2000-2013, using appropriate statistical methods that allow 
comparisons to be made over time and between different populations. A more detailed 
assessment of survival was also performed, evaluating Kuwait’s diagnostic activity, 
examining stage-specific survival for 10 cancers, and comparing stage-specific survival 
between Kuwait and in the US. Finally, this thesis offered a comprehensive evaluation 
of the Kuwaiti cancer care system, using the three major cancer control metrics 
(incidence, survival and mortality), thus assessing progress. The findings showed that 
survival has improved for many cancers during 2000-2013. However, they have also 
highlighted the importance of more complete collection of stage data, the necessity of 
improving early detection, and the need for systematic production and assessment of 
cancer control measures in Kuwait. 
While this thesis presents a broad overview of the current cancer care system in Kuwait, 





allow the efforts in collecting and analysing data performed as part of this thesis to be 
continued, and for more factors to be addressed and evaluated to improve cancer 
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